celz_10q.htm

0001477932-22-008323.txt : 20221110 0001477932-22-008323.hdr.sgml : 20221110 20221110164537 ACCESSION NUMBER: 0001477932-22-008323 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001187953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870622284 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41120 FILM NUMBER: 221378082 BUSINESS ADDRESS: STREET 1: 211 E. OSBORN RD. CITY: PHOENIX STATE: AZ ZIP: 85012 BUSINESS PHONE: 480-399-2822 MAIL ADDRESS: STREET 1: 211 E. OSBORN RD. CITY: PHOENIX STATE: AZ ZIP: 85012 FORMER COMPANY: FORMER CONFORMED NAME: JOLLEY MARKETING INC DATE OF NAME CHANGE: 20020910 10-Q 1 celz_10q.htm FORM 10-Q celz_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number: 000-53500

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Nevada		87-0622284
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

211 E Osborn Road, Phoenix, AZ		85012
(Address of principal executive offices)		(Zip Code)

(480) 399-2822

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CELZ		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports). Yes ☒ No ☐

Indicate by check mark whether the registrant has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the registrant’s common stock on November 10, 2022, was 14,076,246.

		Page Number
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements

	Unaudited Condensed Consolidated Balance Sheets	3

	Unaudited Condensed Consolidated Statements of Operations	4

	Unaudited Condensed Consolidated Statements of Cash Flows	5

	Unaudited Condensed Consolidated Statements of Stockholders’ (Equity)	6

	Notes to Unaudited Condensed Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	22

Item 4.	Controls and Procedures	22

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	23

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23

Item 6.	Exhibits	23

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2022			December 31, 2021
ASSETS
CURRENT ASSETS
Cash	$	16,969,063		$	10,723,870
Certificates of deposit		5,021,307			-
Accounts receivable		-			2,485
Inventory		15,894			10,866
Total Current Assets		22,006,264			10,737,221

OTHER ASSETS
Other assets		3,281			3,281
Licenses, net of amortization		458,616			527,679
TOTAL ASSETS	$	22,468,161		$	11,268,181

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
Accounts payable	$	327,843		$	761,862
Accrued expenses		54,920			24,385
Management fee and patent liabilities - related parties		-			250,000
Advances from related party		14,194			14,194
Total Current Liabilities		396,957			1,050,441

Commitments and contingencies

STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 25,000,000,000 and 6,000,000,000 shares authorized; 14,076,246 and 6,338,872 issued and 14,076,238 and 6,338,864 outstanding at September 30, 2022 and December 31, 2021, respectively		14,077			6,339
Additional paid-in capital		69,653,293			53,879,215
Accumulated deficit		(47,596,166	)		(43,667,814	)
TOTAL STOCKHOLDERS' EQUITY		22,071,204			10,217,740

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	22,468,161		$	11,268,181

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the Three Months Ended September 30, 2022			For the Three Months Ended September 30, 2021			For the Nine Months Ended September 30, 2022			For the Nine Months Ended September 30, 2021

Revenues	$	55,000		$	10,000		$	70,000		$	20,000

Cost of revenues		16,000			4,000			22,791			8,500

Gross profit		39,000			6,000			47,209			11,500

OPERATING EXPENSES
Research and development		230,940			59,180			900,635			59,180
Selling, general and administrative		805,461			757,235			3,043,946			1,536,479
Amortization of patent costs		23,021			23,021			69,063			69,063
TOTAL EXPENSES		1,059,422			839,436			4,013,644			1,664,722

Operating loss		(1,020,422	)		(833,436	)		(3,966,435	)		(1,653,222	)

OTHER INCOME/(EXPENSE)
Interest expense		-			(1,305,273	)		-			(1,875,687	)
Gain on extinguishment of convertible notes		-			489,157			-			585,601
Change in fair value of derivatives liabilities		-			(194,044	)		-			26,030,549
Other income		38,083			-			38,083			-
Total other income (expense)		38,083			(1,010,160	)		38,083			24,740,463

INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES		(982,339	)		(1,843,596	)		(3,928,352	)		23,087,241

Provision for income taxes		-			-			-			-

NET INCOME (LOSS)	$	(982,339	)	$	(1,843,596	)	$	(3,928,352	)	$	23,087,241

BASIC NET INCOME (LOSS) PER SHARE	$	(0.07	)	$	(0.75	)	$	(0.40	)	$	9.98

DILUTED NET INCOME (LOSS) PER SHARE	$	(0.07	)	$	(0.75	)	$	(0.40	)	$	9.77

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC		14,068,412			2,452,076			9,872,450			2,313,005

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - DILUTED		14,068,412			2,452,076			9,872,450			2,363,145

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED CASH FLOWS

	For the Nine Months Ended September 30, 2022			For the Nine Months Ended September 30, 2021

CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	(3,928,352	)	$	23,087,241
Adjustments to reconcile net income (loss) to
net cash from operating activities:
Stock-based compensation		59,584			595,380
Amortization		69,063			69,063
Amortization of debt discounts		-			1,755,104
Change in fair value of derivatives liabilities		-			(26,030,549	)
Increase in principal and accrued interest balances due to penalty provision		-			93,821
Gain on extinguishment of convertible notes		-			(585,601	)
Changes in assets and liabilities:
Accounts receivable		2,485			-
Inventory		(5,028	)		-
Accounts payable		(434,019	)		103,626
Accrued expenses		30,535			26,169
Management fee payable		-			(168,700	)
Net cash used in operating activities		(4,205,732	)		(1,054,446	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of certificates of deposit		(5,021,307	)		-
Advance to related party		-			(200,000	)
Net cash used in investing activities		(5,021,307	)		(200,000	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock and warrants, net of issuance costs		15,471,775			-
Proceeds from exercise of warrants		457			-
Proceeds from note payable		-			3,887,750
Payments on notes payable		-			(105,000	)
Payment of debt issuance costs		-			(443,239	)
Payment of deferred offering costs		-			(3,282	)
Proceeds from convertible notes payable		-			435,040
Proceeds from sale of preferred stock		-			462,000
Related party advances		-			226,500
Repayment of related party advances		-			(220,000	)
Payments to settle convertible notes payable and warrants		-			(705,405	)
Net cash provided by financing activities		15,472,232			3,534,364

NET INCREASE IN CASH		6,245,193			2,279,918
BEGINNING CASH BALANCE		10,723,870			98,012
ENDING CASH BALANCE	$	16,969,063		$	2,377,930

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	$	-		$	9,186
Cash payments for income taxes	$	-		$	-

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accrued dividends on preferred stock	$	-		$	27,725
Warrants issued with notes payable as a service fee	$	-		$	2,097,629
Conversion of notes payable, accrued interest and derivative liabilities into common stock	$	-		$	13,747,415
Conversion of management fees and patent liability into common stock	$	250,000		$	50,000
Discounts on convertible notes payable due to derivative liabilities	$	-		$	134,640
Exchange of preferred stock for notes payable	$	-		$	572,275

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Equity
December 31, 2021		-	$	-		-	$	-		-	$	-		6,338,864	$	6,339	$	53,879,215		$	(43,667,814	)	$	10,217,740

Issuance of common stock and accompanying warrants, net of issuance costs		-		-		-		-		-		-		2,991,669		2,992		15,468,783			-			15,471,775

Common stock issued for related party patent liabilities		-		-		-		-		-		-		181,818		182		249,818			-			250,000

Common stock issued for warrant exercise		-		-		-		-		-		-		4,563,887		4,564		(4,107	)		-			457

Stock-based compensation		-		-		-		-		-		-		-		-		59,584			-			59,584

Net loss		-		-		-		-		-		-		-		-		-			(3,928,352	)		(3,928,352	)

September 30, 2022		-	$	-		-	$	-		-	$	-		14,076,238	$	14,077	$	69,653,293		$	(47,596,166	)	$	22,071,204

	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Equity
June 30, 2022		-	$	-		-	$	-		-	$	-		13,956,238	$	13,957	$	69,644,239		$	(46,613,827	)	$	23,044,369

Common stock issued for warrant exercise		-		-		-		-		-		-		120,000		120		(108	)		-			12

Stock-based compensation		-		-		-		-		-		-		-		-		9,162			-			9,162

Net loss		-		-		-		-		-		-		-		-		-			(982,339	)		(982,339	)

September 30, 2022		-	$	-		-	$	-		-	$	-		14,076,238	$	14,077	$	69,653,293		$	(47,596,166	)	$	22,071,204

Table of Contents

	Series A Preferred Stock				Series B Preferred Stock						Series C Preferred Stock						Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Shares		Amount		Shares			Amount			Shares			Amount			Shares		Amount		Capital			Deficit			Deficit
December 31, 2020		3,000,000	$	3,000		-		$	-			-		$	-			1,537,073	$	1,537	$	22,082,689		$	(61,890,236	)	$	(39,803,010	)

Proceeds from sales of preferred stock		-		-		350			321,000			150			141,000			4,286		4		(4	)		-			462,000

Common stock issued for related party management liabilities		-		-		-			-			-			-			89,286		89		49,911			-			50,000

Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		-		-		-			-			-			-			789,727		790		1,382,541			-			1,383,331

Relief of derivative liabilities		-		-		-			-			-			-			-		-		12,364,084			-			12,364,084

Dividends on preferred stock		-		-		-			-			-			-			-		-		(27,725	)		-			(27,725	)

Cashless exercise of warrants		-		-		-			-			-			-			37,870		38		(38	)		-			-

Warrants issued with notes payable		-		-		-			-			-			-			-		-		2,097,629			-			2,097,629

Preferred stock redemption		-		-		(350	)		(321,000	)		(150	)		(141,000	)		-		-		(110,275	)		-			(572,275	)

Stock-based compensation		-		-		-			-			-			-			-		-		595,380			-			595,380

Net income		-		-		-			-			-			-			-		-		-			23,087,241			23,087,241

September 30, 2021		3,000,000	$	3,000		-		$	-			-		$	-			2,458,242	$	2,458	$	38,434,192		$	(38,802,995	)	$	(363,345	)

	Series A Preferred Stock				Series B Preferred Stock						Series C Preferred Stock						Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Shares		Amount		Shares			Amount			Shares			Amount			Shares		Amount		Capital			Deficit			Deficit
June 30, 2021		3,000,000	$	3,000		350		$	321,000			150		$	141,000			2,440,614	$	2,440	$	35,777,506		$	(36,959,399	)	$	(714,453	)

Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		-		-		-			-			-			-			17,628		18		153,962			-			153,980

Relief of derivative liabilities		-		-		-			-			-			-			-		-		138,731			-			138,731

Dividends on preferred stock		-		-		-			-			-			-			-		-		(6,973	)		-			(6,973	)

Warrants issued with notes payable		-		-		-			-			-			-			-		-		2,097,629			-			2,097,629

Preferred stock redemption		-		-		(350	)		(321,000	)		(150	)		(141,000	)		-		-		(110,275	)		-			(572,275	)

Stock-based compensation		-		-		-			-			-			-			-		-		383,612			-			383,612

Net loss		-		-		-			-			-			-			-		-		-			(1,843,596	)		(1,843,596	)

September 30, 2021		3,000,000	$	3,000		-		$	-			-		$	-			2,458,242	$	2,458	$	38,434,192		$	(38,802,995	)	$	(363,345	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2022

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization – Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company focused on immunology, urology, orthopedics and neurology using adult stem cell treatments. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly-owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business.

CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AmnioStem LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AmnioStem LLC have commenced commercial activities.

The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively.

On October 20, 2022 the Company announced it has produced an allogenic Cell Line called AlloStem™, which includes a Master Cell Bank and a Drug Master File which shall be submitted for FDA registration. The importance of the company creating and developing such assets, as opposed to licensing agreements with third parties, provides further de-risking of an important component to many of our programs, including, but not limited to, the ImmCelz^® immunotherapy platform for multiple diseases, OvaStem^® for Premature Ovarian Failure, AlloStem™ for Type 1 diabetes, StemSpine^® for lower back pain, and IPSCelz ™ inducible pluripotent stem cell program in ongoing development with Greenstone Biosciences.

In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began exploring the development of an immunotherapy platform that “supercharges” the patients own immune cells. Secreted factors from AlloStem™ cells are used to “reprogram” the patient’s own immune cells. They are then harvested and injected back into the patient in less than 72 hours. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.

On June 15, 2022, the Company signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the development of a human induced pluripotent stem cell (iPSC) pipeline for the Company's ImmCelz® platform. This project is identified as iPScelz^TM. Human iPSc's are genetically reprogrammed to differentiate into a wide array of human cell and tissue types, possess the ability to proliferate almost indefinitely in culture, and represent a single source of cells that could be used to replace those lost to damage or disease. Beyond the therapeutic benefits offered by iPSC, the next generation iPScelz^TM pipeline for ImmCelz® will enable the ability for large scale production and sustainability, while helping to reduce long term costs of manufacturing.

Use of Estimates – The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Table of Contents

Basis of Presentation - The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. The operations for the nine-month period ended September 30, 2022, are not necessarily indicative of the operating results for the full year.

Risks and Uncertainties - The Company has a limited operating history and has only recently started to generate revenues from its planned principal operations.

On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company has experienced a reduction in revenues due to the COVID-19 outbreak.

The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations.

The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time consuming and could delay launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing.

The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones.

Table of Contents

On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company has a 180 day grace period, until January 4, 2023, during which the Company may regain compliance if the bid price of our common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. In addition, the Company may be eligible for an additional 180-day grace period if we meet Nasdaq’s initial listing standards (other than with respect to minimum bid price) for The Nasdaq Capital Market. The Company intends to actively monitor the bid price for our common stock between now and January 4, 2023, and will consider available options to regain compliance with Nasdaq’s minimum bid price requirements. However, there can be no assurance that the Company will be able to regain compliance with Nasdaq’s Listing Rules and maintain our Nasdaq listing. The delisting of our shares of common stock from Nasdaq may have a material negative impact on the liquidity of our securities, as well as a material negative impact on our ability to raise capital in the future.

Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned.

The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer.

Payments received for which the earnings process is not yet complete are deferred. As of September 30, 2022, the Company had no deferred revenue.

Concentration Risks - The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at two financial institutions. As of September 30, 2022, the Company’s balance exceeded the limit at both institutions.

Fair Value of Financial Instrument - The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy:

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of September 30, 2022, the Company has no derivative liabilities.

Table of Contents

Basic and Diluted Loss Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stockholders for the Nine-Months ended September 30, 2021.

	For the Nine- Months Ended September 30, 2021
Weighted average common shares outstanding used in calculating basic earnings per share		2,313,005
Effect of Series B and C preferred stock		-
Effect of warrants		50,140
Effect of convertible notes payable		-
Effect of convertible related party management fee and patent liabilities		-
Weighted average common shares outstanding used in calculating diluted earnings per share		2,363,145

Net income as reported	$	23,087,241
Add - Interest on convertible notes payable		-
Net income available to common stockholders	$	23,087,241

The Company excluded 7 options and 18 warrants from the computation of diluted net income per share for the Nine-Months ended September 30, 2021 as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period.

During the Nine-Months ended September 30, 2022, the Company had 111,824 options and 22,849,272 warrants to purchase shares of common stock which have been excluded from the dilutive net loss per share calculation as their effects are anti-dilutive.

On November 10, 2021, we effected a 1-for-500 reverse split of our authorized and issued and outstanding shares of common stock. All share references have been restated for this reverse split to the earliest period presented. As a result of the split, the authorized shares of the Company’s common stock decreased to 50,000,000 shares.

Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

Table of Contents

NOTE 2 – LICENSING AGREEMENTS

ED Patent – The Company acquired a patent from CMH, a related company on February 2, 2016, in exchange for 431,111 shares of CMTH restricted common stock valued at $100,000. The patent expires in 2025 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $7,479 was recorded for the Nine-Months ended September 30, 2022 and 2021. As of September 30, 2022, the carrying value of the patent was $33,507. The Company expects to amortize $9,972 annually through 2026 related to the patent costs.

Multipotent Amniotic Fetal Stem Cells License Agreement - On August 25, 2016, CMT entered into a License Agreement dated August 25, 2016, with a University. This license agreement grants to CMT the exclusive right to all products derived from a patent for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. The license agreement also permits CMT to grant sublicenses. Under the terms of the license agreement, CMT is required to diligently develop, manufacture, and sell any products licensed under the agreement. CMT paid the University an initial license fee within 30 days of entering into the agreement. CMT is also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments and earned royalties on the net sales of licensed products by CMT or any sub licensee. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sub licensee. As of September 30, 2022, no amounts are currently due to the University.

The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $879 was recorded for the Nine-Months ended September 30, 2022 and 2021. As of September 30, 2022, the carrying value of the patent was $3,498. The Company expects to amortize approximately $1,172 annually through 2026 related to the patent costs.

Lower Back Patent – The Company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017. As amended, the agreement provides the following:

	·	The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.
	·	In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:

	o	$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.
	o	$200,000, upon completion of the IRB clinical trial.
	o	$300,000 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.

In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:

	o	$100,000 upon filing an IND with the FDA.
	o	$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.
	o	$400,000 upon dosing the first patient in a Phase 3 clinical trial.

Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date.

In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.

For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.

Table of Contents

The Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 6,667 shares of common stock on December 12, 2019. On January 8, 2021, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 133 shares of common stock. On September 30, 2020, the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 84,656 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 89,286 shares of common stock. The remaining portion of the $300,000 obligation was paid in cash in 2021.

The patent expires on May 19, 2027 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $7,500 was recorded for the nine-month periods ended September 30, 2022 and 2021. As of September 30, 2022, the carrying value of the initial patent license was $47,500. The Company expects to amortize approximately $10000 annually through 2027 related to the patent costs.

The Company has elected to amortize the increased obligation from the election to commercialize the StemSpine technology over a ten-year period on a straight-line basis. Amortization expense of $34,455 was recorded for the nine-month periods ended September 30, 2022 and 2021. As of September 30, 2022, the carrying value of the patent was $167,859. The Company expects to amortize approximately $46,000 annually through 2027 related to the patent costs.

ImmCelz™ - On December 28, 2020, ImmCelz, Inc. (“ImmCelz”), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a former director of the Company. The Agreement grants to ImmCelz™ the patent rights under U.S. Patent# 9,803,176 B2, “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses”. The contract grants ImmCelz™ access to proprietary process of expanding the master cell bank of Jadi Cell LLC, as currently practiced by Licensor and as documented in standard operating procedures (SOPs) and other written documentation. The terms of the agreement are as follows:

Licensee shall pay Licensor a license fee of $250,000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement

Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty”)

in one or a series of related transactions, of all or substantially all of the business or assets of Licensee ImmCelz, Inc. (“Sale of Assets”) will result in a one-time ten-percent allocation to the licensor, the Continuing Royalty will be calculated at five percent (5%) of the Net Income of Licensee in any calendar quarter in which the Net Income in such calendar quarter reflects the receipt of any consideration from such Sale of Assets.

To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 180,180 shares of common stock to Jadi Cell in February 2022.

The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $18,750 were recorded for the nine-month periods ended September 30, 2022 and 2021. As of September 30, 2022, the carrying value of the patent was $206,250. The Company expects to amortize approximately $25,000 annually through 2030 related to the patent costs.

Table of Contents

The following is a roll-forward of the Company’s licensing agreements for the Nine-Months ended September 30, 2022.

	Assets		Accumulated Amortization

Balances at December 31, 2021	$	760,000	$	(232,321	)
Addition of new assets				-
Amortization		-		(69,063	)
Balances at September 30, 2022	$	760,000	$	(301,384	)

NOTE 3 – RELATED PARTY TRANSACTIONS

Management Reimbursement Agreement

On November 17, 2017, the Company entered into a Management Reimbursement Agreement with CMH, a related party whose directors and executive officers include the Company’s officers and directors. Pursuant to this agreement, during 2019 and 2020, and until September 16, 2021, the Company reimbursed CMH an aggregate of $45,000 per month for the services of management and consultants employed by CMH (including the Company’s Chief Executive Officer and Chief Financial Officer, and the Company’s former directors Dr. Patel and Dr. Ichim). The agreement provided that at the option of CMH, the reimbursable amounts may be paid from time to time in shares of common stock of the Company at a price equal to a 30% discount to the lowest closing price during the 20 trading days prior to time the notice is given. This agreement was terminated effective September 15, 2021. At September 30, 2021 and 2022, no amounts were owed CMH under this agreement.

Debt Settlement Agreement

On January 12, 2018, the Company entered into a Debt Settlement Agreement with Timothy Warbington, the Company’s Chief Executive Officer, under which the Company issued 3,000,000 shares of super-voting Series A Preferred Stock to Mr. Warbington in exchange for the cancellation of $150,000 of debt owed by the Company to CMH, which CMH in turn was obligated to pay Mr. Warbington. The Series A Preferred Stock previously provided Mr. Warbington with substantial control over all matters subject to a vote of the Company’s shareholders. Mr. Warbington surrendered the Series A Preferred Stock to the Company in December 2021 immediately prior to the closing of the Company’s public offering in exchange for $150,000 plus 8% interest on such amount from January 2018 until the date of surrender.

Jadi Cell License Agreement

On December 28, 2020, the Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company. The agreement provides Company with an exclusive, worldwide license to U.S. Patent No. 9,803,176 “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses” and the proprietary process of expanding the master cell bank of Jadi Cell LLC, in the field of enhancing autologous cells. The agreement is described in detail in Note 2 above. To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 181,818 shares of common stock to Jadi Cell in February 2022.

StemSpine Patent Purchase

The Company acquired U.S. Patent No. 9,598,673 covering the use of various stem cells for the treatment of lower back pain from its affiliate CMH pursuant to a Patent Purchase Agreement dated May 17, 2017, which was amended in November 2017. The inventors of the patent were Thomas Ichim, PhD and Amit Patel, MD, former directors of the Company, and Annette Marleau, PhD. The Patent Purchase Agreement is described in detail in Note 2 above. Pursuant to the Patent Purchase Agreement, the Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 6,667 shares of common stock on December 12, 2020. On January 8, 2021, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 133 shares of common stock. On September 30, 2020, the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 84,656 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 89,286 shares of common stock. The remaining portion of the $300,000 obligation has been paid in cash.

Table of Contents

Insider Loans

On May 28, 2021, Timothy Warbington, who is our CEO and Chairman; and Dr. Amit Patel, who was formerly a director of ours, advanced the Company $50,000 and $150,000 respectively. The two notes were repaid during the quarter ended September 30, 2021, did not have any conversion features, and bore interest at the rate of 5% per annum.

NOTE 4 – DEBT

As-of September 30, 2022, the Company had no outstanding loans and there was no loan activity during the Nine-Months ended September 30, 2022.

On August 11, 2021, we completed the sale of 15% Original Issue Discount Senior Notes (“Bridge Notes”) in the aggregate principal amount of $4,456,176 to a group of institutional investors (the “Purchasers”). In connection with the sale of the Bridge Notes, holders of our shares of Series B Preferred Stock and Series C Preferred Stock exchanged such preferred stock for additional Bridge Notes in the aggregate principal amount of $690,000. The Bridge Notes were scheduled to mature on February 11, 2022, subject to the requirement that we redeem the Bridge Notes prior to such date with the net proceeds of any future offering of our securities. The notes were redeemed in full as a result of the securities offering on December 7, 2021. The Notes did not bear interest other than upon an event of default, and were not convertible into the Company’s common stock. In addition, the Notes were subject to covenants, events of defaults and other terms and conditions customary in transactions of this nature. The Company amortized the on-issuance discount and financing fees totaling $758,426 to interest expense with respect to these notes.

The Company also issued to the purchasers of the Bridge Notes five-year warrants to purchase an aggregate of 363,046 shares of our common stock at an initial exercise price of $14.175 per share, subject to anti-dilution adjustment in the event of future sales of our equity below the then exercise price, stock dividends, stock splits and other specified events.

Roth Capital Partners (“Roth”), acted as sole placement agent for the offering. Pursuant to terms of an engagement letter with Roth, the Company paid Roth a placement agent fee in the amount $312,750. The Company also issued Roth a warrant to purchase 20,189 shares of common stock with the same terms as the warrants issued to the Purchasers.

During the nine-months ended September 30, 2021, we also issued $498,800 in convertible notes to accredited investors with net proceeds of $435,040, which have since been repaid in full. The notes were to mature during February and July of 2022 and bore interest at a rate of 8%. The notes were convertible into shares of the Company’s common stock at conversion prices ranging from 60% to 71% of the average of the two lowest traded prices or the lowest trade price of the Company’s common stock during the previous 15 trading days preceding the conversion date. The Company amortized the discount due to derivative liabilities and on-issuance discount totaling $443,905 to interest expense with respect to these notes.

On May 28, 2021, Mr. Timothy Warbington, who is our CEO and Chairman; and Dr. Amit Patel, who is a director of ours, advanced the company $50,000 and $150,000 respectively. The two notes were repaid during the quarter ended September 30, 2021, did not have any conversion features, and bore interest at the rate of 5% per annum.

Table of Contents

On June 21, 2021, we issued a $105,000, non-convertible note to an accredited investor with net proceeds of $100,000. The note was repaid during the quarter ended September 30, 2021, did not have any conversion features, and bore interest at the rate of 10% per annum.

During the nine-months ended September 30, 2022 there was no amortization to interest expense. During the nine-months ended September 30, 2021, the Company amortized $1,755,104 to interest expense. As of September 30, 2022, total discounts were $0.

During the nine-months ended September 30, 2021, the Company issued an aggregate of 789,727 shares upon the conversion of $1,383,331 of outstanding principal, interest and fees on outstanding notes, and 37,870 shares upon the cashless exercise of 43,167 warrants.

NOTE 5 – DERIVATIVE LIABILITIES

Derivative Liabilities

As-of September 30, 2022, the Company had no outstanding derivative liabilities and there was no derivative activity during the Nine-Months ended September 30, 2022.

In connection with convertible notes payable, the Company records derivative liabilities for the conversion feature. The derivative liabilities are valued on the date the convertible note payable become convertible and revalued at each reporting period. During the nine-months ended September 30, 2021, the Company recorded initial derivative liabilities of $1,077,757 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of $0.0106 to $0.0248 our stock price on the date of grant of $0.0340 to $0.0806, expected dividend yield of 0%, expected volatility of 75.03% to 98.14%, risk free interest rate of 0.10% and expected terms of 1.0 year. Upon initial valuation, the derivative liabilities exceeded the face values certain of the convertible notes payable by approximately $697,602, which was recorded as a day one loss in derivative liability.

In August 2021, we completed the sale of 15% Original Issue Discount Senior Notes (“Bridge Notes”) in the aggregate principal amount of $4,456,176 to a group of institutional investors (the “Purchasers”). A portion of the proceeds were used to repay the principal, accrued interest, pre-payment fees and other premiums of all the outstanding convertible notes as well as all previously outstanding warrants with re-pricing and anti-dilutive features. The result was $0 in derivative liabilities as-of the period ended September 30, 2021.

NOTE 6 – STOCK-BASED COMPENSATION

On September 6, 2021, the Company’s Board of Directors and holders of a majority of the voting power of the Company’s stockholders approved the Company’s 2021 Equity Incentive Plan (the “2021 Plan”), and reserved 600,000 shares of common stock for the issuance of awards thereunder. The 2021 Plan provides for the granting to our employees, officers, directors, consultants and advisors of performance awards payable in shares of common stock, stock options (non-statutory and incentive), restricted stock awards, stock appreciation rights (“SARs”), restricted share units (“RSUs”) and other stock-based awards. The purpose of the 2021 Plan is to secure for the Company and its stockholders the benefits arising from capital stock ownership by eligible participants who are expected to contribute to the Company’s future growth and success.

During the Nine-Months ended September 30, 2022, Messrs. Warbington and Dickerson received 10-year options to purchase an aggregate of 111,187 shares of common stock with an exercise price of $1.69. The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date. The value of the options was determined to be $145,525 based upon the Black-Scholes method, see variables used below.

	Inputs Used

Annual dividend yield	$	-
Expected life (years)		10.0
Risk-free interest rate		0.81	%
Expected volatility		92.95	%
Common stock price	$	1.69

Table of Contents

During the Nine-Months ended September 30, 2021, the fair market value of the options was insignificant to the financial statements.

Since the expected life of the options was greater than the Company’s historical stock information available, the Company determined the expected volatility based on price fluctuations of comparable public companies.

There were no options issued during the Nine-Months ended September 30, 2021.

Option activity for the Nine-Months ended September 30, 2022 consists of the following:

	Stock Options		Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2021		7	$	7,500		4.64
Issued		111,817				-
Exercised		-		-		-
Expired		-		-		-
Outstanding, September 30, 2022		111,824	$	2.16		9.32
Vested, September, 30, 2022		27,961	$	3.57		9.32

NOTE 7 – STOCKHOLDERS’ EQUITY

On May 3, 2022, the “Company” completed the sale of (i) 2,991,669 shares of common stock, and pre-funded warrants to purchase 4,563,887 shares of common stock (the “Pre-Funded Warrants”), and (ii) accompanying warrants to purchase 15,111,112 shares of common stock (the “Common Warrants”), at a combined offering price of $2.25 per share of common stock/Pre-Funded Warrant and related Common Warrant, to a group of institutional investors (the “Purchasers”), pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder.

The Common Warrants have a five-year term, and an exercise price of $2.00 per share. The Pre-Funded Warrants do not expire, and have an exercise price of $0.0001 per share.

The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.

Roth Capital Partners (“Roth”), acted as sole placement agent for the offering. The Company paid Roth a placement agent fee in the amount $1,360,000, and issued Roth a warrant to purchase 1,133,333 shares of Common Stock with the same terms as the Common Warrants issued to the Purchasers.

The issuances and exercises during the Nine-Months ended September 30, 2022, are as follows:

Outstanding at December 31, 2021		6,604,820
Issuances		20,808,332
Exercises		(4,563,887	)
Outstanding at September 30, 2022		22,849,272
Weighted Average Price at September 30, 2022	$	2.66

NOTE 8 – SUBSEQUENT EVENTS

In accordance with ASC 855, management reviewed all material events through November 15, 2022, for these financial statements. The material subsequent events are as follows:

On November 3, 2022 the Company announced he U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application, enabling the Company to proceed with initiating a clinical trial for Type 1 Diabetes using AlloStem™ AlloStem™ leverages a unique approach to harnessing the power of Perinatal Tissue Derived Cells® (PRDC) to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, and large-scale clinical expansion. The primary objective of the study (CELZ-201) is to evaluate AlloStem™ in patients with newly diagnosed Type 1 Diabetes. Patient recruitment is expected to begin in Q1 2023 with trial commencement updates to follow.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of operations. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2021, and our interim financial statements and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.

Forward-Looking Statement Notice

This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

Table of Contents

Overview

We are a commercial stage biotechnology company focused on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. Our existing and pipeline of therapies and products include of the following:

Our subsidiary, Creative Medical Technologies, Inc. (“CMT”), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired in February 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AmnioStem LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AmnioStem LLC have commenced commercial activities.

We currently conduct substantially all of our commercial operations through CMT, which markets and sells our CaverStem^® and FemCelz^®disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem^® and FemCelz^® kits are currently available through physicians at eight locations in the United States.

The Company has produced an allogenic Cell Line called AlloStem™, which includes a Master Cell Bank and a Drug Master File which shall be submitted for FDA registration. This is an important component to many of our programs, including, but not limited to, the ImmCelz^® immunotherapy platform for multiple diseases, OvaStem^® for Premature Ovarian Failure, AlloStem™ for Type 1 diabetes, StemSpine^® for lower back pain, and IPSCelz ™ inducible pluripotent stem cell program in ongoing development with Greenstone Biosciences.

The Company is working with Greenstone Biosciences Inc. in Palo Alto, CA to develop a human induced pluripotent stem cell (iPSC) pipeline for the Company's ImmCelz® platform. The project is identified as iPScelz^TM. Human iPSc's are genetically reprogrammed to differentiate into a wide array of human cell and tissue types, possess the ability to proliferate almost indefinitely in culture, and represent a single source of cells that could be used to replace those lost to damage or disease. Beyond the therapeutic benefits offered by iPSC, the next generation iPScelz^TM pipeline for ImmCelz® will enable the ability for large scale production and sustainability, while helping to reduce long term costs of manufacturing.

Results of Operations – For the Three-month Periods Ended September 30, 2022 and 2021

Gross Revenue. We generated $55,000 in revenue for the three-month period ended September 30, 2022, in comparison with $10,000 for the comparable quarter a year ago. The increase of $45,000 or 450% was primarily due to new physician recruitment.

Table of Contents

Cost of Goods Sold. We generated $16,000 of cost of goods sold for the three-month period ended September 30, 2022, in comparison with $4,000 cost of goods sold for the comparable period a year ago. The increase of $12,000 or 300% was due to the increased sales.

Gross Profit/(Loss). We generated a gross profit of $39,000 for the three-month period ended September 30, 2022, in comparison with $6,000 gross profit for the comparable period a year ago. The increase of $33,000 or 550% was due to the increased sales.

General and Administrative Expenses. General and administrative expenses for the three-month period ended September 30, 2022, totaled $805,461 in comparison with $757,235, for the comparable quarter a year ago. The increase of $48,226 or 6% is primarily due to approximately $87,000 in director and officer insurance premiums that began in September 2021, an increase of approximately $164,000 in increased net salary expenses from terminating the management service agreement in September 2021 and entering into direct employment arrangements with our CEO, CFO and the hiring of other key leaders of the management team, an increase of approximately $58,000 in marketing expenses as we ramp-up our commercial activity, and an increase of $139,000 in outside consulting expenses focused on moving key elements of our programs forward along with investments in intellectual property, offset by a reduction of $374,000 in stock-based compensation.

Amortization Expenses. Amortization expenses for the three-month periods ended September 30, 2022 and 2021, totaled $23,021.

Research and Development Expenses. Research and development expenses for the three-month period ended September 30, 2022, totaled $230,940 in comparison with $59,180, for the comparable quarter a year ago. The increase of $171,760 or 290% reflects investments in in regulatory, research, laboratory and manufacturing resources required to move our programs forward.

Other Income/Expense. Other income for the three-month period ended September 30, 2022 was $38,083, in comparison with a loss of $1,010,160, for the comparable quarter a year ago. The increased income of $1,048,243, is driven by the elimination of convertible debt that eliminated interest expense in 2022 compared to $1,305,273 in 2021, a loss of $184,044 on the change of fair value of derivative liabilities in 2021, offset by a gain of $489, 157 from the extinguishment of convertible notes in 2021 and $38,083 in interest income from short-term certificate of deposit investments in 2022.

Net Income/Loss. For the reasons stated above, our net loss for the three-month period ended September 30, 2022, totaled $982,339 in comparison to a loss of $1,010,160, for the comparable quarter a year ago.

Results of Operations – For the Nine-month Periods Ended September 30, 2022 and 2021

Gross Revenue. We generated $70,000 in revenue for the nine-month period ended September 30, 2022, in comparison with $20,000 in revenue for the comparable period a year ago. The increase of $50,000 or 250% was primarily due to new physician recruitment.

Cost of Goods Sold. We generated $22,791 of cost of goods sold for the nine-month period ended September 30, 2022, in comparison with $8,500 cost of goods sold for the comparable period a year ago. The increase of $14,291 or 168% was primarily due to new physician recruitment.

Gross Profit/(Loss). We generated a gross profit of $47,209 for the nine-month period ended September 30, 2022, in comparison with $11,500 gross profit for the comparable period a year ago. The increase of $35,709 or 311% was due to the increased sales.

Table of Contents

General and Administrative Expenses. General and administrative expenses for the nine-month period ended September 30, 2022, totaled $3,043,946 in comparison with $1,536,479, for the comparable period a year ago. The increase of $1,507,467 or 98% is primarily due to approximately $392,000 in director and officer insurance premiums that began in September 2021, an increase of approximately $542,000 in increased net salary expenses offset by the termination of the management service agreement in September 2021 and entering into direct employment arrangements with our CEO, CFO and the hiring of other key leaders of the management team, $226,000 in Board of Director expenses as a result of bringing on independent board members, an increase of approximately $337,000 in marketing expenses, and an increase of $381,000 in outside consulting expenses focused on moving key elements of our programs forward along with investments in intellectual property offset by a $536,000 reduction in stock-based compensation.

Amortization Expenses. Amortization expenses for the nine-month periods ended September 30, 2022 and 2021, totaled $69,063.

Research and Development Expenses. Research and development expenses for the nine-month period ended September 30, 2022, totaled $900,635 in comparison with $59,180, for the comparable period a year ago. The increase of $841,455 or 1,422% reflects investments in in regulatory, research, laboratory and manufacturing resources required to move our programs forward.

Other Income/Expense. Other income for the nine-month period ended September 30, 2022 was $38,083, in comparison with 24,740,463, for the comparable period a year ago. The decreased income of $24,702,380, is primarily driven by the 2021 gain of $26,030,549 in the change in the fair value of derivative liabilities and a gain of $585,601 on the extinguishment of convertible notes, offset by interest expense of $1,875,687 in 2021 that was tied to convertible debt.

Net Income/Loss. For the reasons stated above, our net loss for the nine-month period ended September 30, 2022, totaled $3,928,352 in comparison to net income of $23,087,241, for the comparable period a year ago.

Liquidity and Capital Resources

As of September 30, 2022, we had $21,990,370 of available cash and short-term certificates of deposit and positive working capital of approximately $21,609,307. In comparison, as of December 31, 2021, we had approximately $10,723,807 of available cash and positive working capital of approximately $9,686,780.

On December 7, 2021, we sold an aggregate of 3,875,000 shares of our common stock, and accompanying warrants to purchase 3,875,000 shares of common stock at an exercise price of $4.13 per share, at a combined public offering price to the public of $4.13 per share of common stock and related Warrant, pursuant to an Underwriting Agreement we entered into with Roth Capital Partners, LLC. We received gross proceeds of $16,003,750, before deducting underwriting discounts and commissions of seven percent (7%) of the gross proceeds and offering expenses. We used a portion of the proceeds from the offering to (i) redeem our Bridge Notes described below, in the aggregate outstanding amount of $5,146,176, and (ii) repurchase the Company’s Series A Preferred Stock from the Company’s Chief Executive Officer for an aggregate purchase price of approximately $195,000.

In addition, on May 3, 2022 we completed the sale of (i) 2,991,669 shares of common stock and pre-funded warrants to purchase 4,563,887 shares of common stock, and (ii) accompanying warrants to purchase 15,111,112 shares of common stock, at a combined offering price of $2.25 per share of common stock/Pre-Funded Warrant and related Common Warrant, to a group of institutional investors, resulting in gross proceeds to the Company of approximately $17,000,000.

Cash Flows

Net Cash used in Operating Activities. We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $4,205,732 for the nine-month period ended September 30, 2022 in comparison to $1,054,446 for the comparable period a year ago, an increase of $3,151,286 or 299%. The increase in cash used in operations was primarily related to the increased expenses mentioned above.

Net Cash used in Investing Activities. There was $5,021,307 cash used to invest in short-term certificates of deposit in the nine-month period ended September 30, 2022 compared to $200,000 used as an advance to a related party for comparable period a year ago.

Table of Contents

Net Cash From Financing Activities. We raised $15,472,232 during the nine-month period ended September 30, 2022 through the issuance of common stock and pre-paid warrants, net of offering costs. We raised $3,534,364 through the issuance of convertible debt, preferred stock and a related party advance in the nine-month period ended September 30, 2021.

Critical Accounting Policies and Estimates

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles accepted in the United States. In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time our consolidated financial statements are prepared. On a regular basis, we review the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we have elected not to provide the disclosure required by this item.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

As required by Rule 13a-15 under the Exchange Act, our management evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2022.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 15(d)-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. As of September 30, 2022 we were not involved in any legal proceedings.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In February 2022, we paid the initial Jadi Cell obligation of $250,000 through the issuance of 181,818 shares of common stock.

Item 6. Exhibits

SEC Ref. No.		Title of Document

3.1.1		Articles of Incorporation of Creative Medical Technology Holdings, Inc., a Nevada corporation (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2021).
3.1.2		Certificate of Designation of the Series A Preferred Stock of the Company (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 16, 2018).
3.1.3		Certificate of Amendment to Certificate of Designation of the Series A Preferred Stock Pursuant to NRS 78.1955, filed with the Secretary of State of the State of Nevada on March 11, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2021).
3.1.4		Certificate of Designation of the Series B Preferred Stock of the Company, filed March 30, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2021).
3.1.5		Certificate of Designation of the Series C Preferred Stock of the Company, filed March 30, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 2, 2021).
3.1.6		Certificate of Amendment to Articles of Incorporation Pursuant to NRS 78.385 and 78.390, as filed with the Secretary of State of the State of Nevada on November 2, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2021).
3.1.7		Certificate of Withdrawal of Certificate of Designation of Series B Convertible Preferred Stock, as filed with the Secretary of State of the State of Nevada on November 2, 2021 (incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2021).
3.1.8		Certificate of Withdrawal of Certificate of Designation of Series C Convertible Preferred Stock, as filed with the Secretary of State of the State of Nevada on November 2, 2021 (incorporated by reference to Exhibit 3.3 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2021).
3.1.9		Certificate of Change Pursuant to NRS 78.209, as filed with the Secretary of State of the State of Nevada on November 8, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 9, 2021).
3.2		Bylaws of Creative Medical Technology Holdings, Inc., a Nevada corporation (incorporated by reference to Exhibit 3.2 to the Company’s Form 10 filed with the Securities and Exchange Commission on November 18, 2008).
31.1		Rule 13a-14(a) Certification by Principal Executive Officer
31.2		Rule 13a-14(a) Certification by Principal Financial Officer
32.1		Section 1350 Certification of Principal Executive Officer
32.2		Section 1350 Certification of Principal Financial Officer
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Creative Medical Technology Holdings, Inc.

Date: November 10, 2022	By	/s/ Timothy Warbington
		Timothy Warbington, Chief Executive Officer
		(Principal Executive Officer)

Date: November 10, 2022	By	/s/ Donald Dickerson
		Donald Dickerson, Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 celz_ex311.htm CERTIFICATION celz_ex311.htm

EXHIBIT 31.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Timothy Warbington, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of Creative Medical Technology Holdings, Inc. for the quarter ended September 30, 2022;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)

Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 10, 2022

By:

/s/ Timothy Warbington

Timothy Warbington

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 celz_ex312.htm CERTIFICATION celz_ex312.htm

EXHIBIT 31.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Donald Dickerson, certify that:

1.

I have reviewed this quarterly report on Form 10-Q of Creative Medical Technology Holdings, Inc. for the quarter ended September 30, 2022;

b)

Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 10, 2022

By:

/s/ Donald Dickerson

Donald Dickerson

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 celz_ex321.htm CERTIFICATION celz_ex321.htm

EXHIBIT 32.1

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with this Quarterly Report of Creative Medical Technology Holdings, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, Timothy Warbington, Chief Executive Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

1.

Such Quarterly Report on Form 10-Q for the period ended September 30, 2022, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in such Quarterly Report on Form 10-Q for the period ended September 30, 2022 fairly presents, in all material respects, the financial condition and results of operations of Creative Medical Technology Holdings, Inc

Date: November 10, 2022

By:

/s/ Timothy Warbington

Timothy Warbington

Chief Executive Officer

(Principal Executive Officer)

EX-32.2 5 celz_ex322.htm CERTIFICATION celz_ex322.htm

EXHIBIT 32.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with this Quarterly Report of Creative Medical Technology Holdings, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, Donald Dickerson, Chief Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

1.

Such Quarterly Report on Form 10-Q for the period ended September 30, 2022, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in such Quarterly Report on Form 10-Q for the period ended September 30, 2022, fairly presents, in all material respects, the financial condition and results of operations of Creative Medical Technology Holdings, Inc.

Date: November 10, 2022

By:

/s/ Donald Dickerson

Donald Dickerson

Chief Financial Officer

(Principal Financial Officer)

EX-101.SCH 6 celz-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - LICENSING AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - STOCKBASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - LICENSING AGREEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - STOCKBASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - STOCKHOLDERS EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - LICENSING AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - LICENSING AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - DEBT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - STOCKBASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - STOCKBASED COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - STOCKBASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 celz-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Entity Interactive Data Current CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS CURRENT ASSETS Cash Certificates of deposit Accounts receivable Inventory Total Current Assets [Assets, Current] OTHER ASSETS Other assets Licenses, net of amortization TOTAL ASSETS [Assets] LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable Accrued expenses Management fee and patent liabilities - related parties Advances from related party Total Current Liabilities [Liabilities, Current] Commitments and contingencies STOCKHOLDERS' EQUITY Common stock, $0.001 par value, 25,000,000,000 and 6,000,000,000 shares authorized; 14,076,246 and 6,338,872 issued and 14,076,238 and 6,338,864 outstanding at September 30, 2022 and December 31, 2021, respectively Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERS' EQUITY [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY [Liabilities and Equity] Common Stock, Shares Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Revenues Cost of revenues Gross profit [Gross Profit] OPERATING EXPENSES Research and development Selling, general and administrative Amortization of patent costs TOTAL EXPENSES [Operating Expenses] Operating loss [Operating Income (Loss)] OTHER INCOME/(EXPENSE) Interest expense [Interest Expense] Gain on extinguishment of convertible notes Change in fair value of derivatives liabilities Other income Total other income (expense) [Nonoperating Income (Expense)] INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Provision for income taxes NET INCOME (LOSS) [Net Income (Loss) Attributable to Parent] BASIC NET INCOME (LOSS) PER SHARE DILUTED NET INCOME (LOSS) PER SHARE WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - DILUTED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS CASH FLOWS FROM OPERATING ACTIVITIES: Net income (loss) [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to reconcile net income (loss) to net cash from operating activities: Stock-based compensation Amortization Amortization of debt discounts Change in fair value of derivatives liabilities [Liabilities, Fair Value Adjustment] Increase in principal and accrued interest balances due to penalty provision Gain on extinguishment of convertible notes [Gain (Loss) on Extinguishment of Debt] Changes in assets and liabilities: Accounts receivable [Increase (Decrease) in Accounts Receivable] Inventory [Increase (Decrease) in Inventories] Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Management fee payable Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of certificates of deposit [Payments to Acquire Restricted Certificates of Deposit] Advance to related party [Payments to Fund Long-Term Loans to Related Parties] Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from sale of common stock and warrants, net of issuance costs Proceeds from exercise of warrants Proceeds from note payable Payments on notes payable [Repayments of Notes Payable] Payment of debt issuance costs [Payments of Debt Issuance Costs] Payment of deferred offering costs [Payment of deferred offering costs] Proceeds from convertible notes payable Proceeds from sale of preferred stock Related party advances Repayment of related party advances [Repayments of Related Party Debt] Payments to settle convertible notes payable and warrants [Repayments of Convertible Debt] Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] NET INCREASE IN CASH [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect] BEGINNING CASH BALANCE [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] ENDING CASH BALANCE SUPPLEMENTAL CASH FLOW INFORMATION: Cash payments for interest Cash payments for income taxes NON-CASH INVESTING AND FINANCING ACTIVITIES: Accrued dividends on preferred stock Warrants issued with notes payable as a service fee Conversion of notes payable, accrued interest and derivative liabilities into common stock Conversion of management fees and patent liability into common stock Discounts on convertible notes payable due to derivative liabilities Exchange of preferred stock for notes payable UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Series A, Preferred Stock Series B, Preferred Stock Series C, Preferred Stock Balance, shares [Shares, Issued] Balance, amount Proceeds from sales of preferred stock, shares Proceeds from sales of preferred stock, amount Common stock issued for related party management liabilities, shares Common stock issued for related party management liabilities, amount Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount Relief of derivative liabilities Dividends on preferred stock Cashless exercise of warrants, shares Cashless exercise of warrants, amount Warrants issued with notes payable Preferred stock redemption, shares Preferred stock redemption, amount Stock-based compensation [Stock-based compensation] Net income Issuance of common stock and accompanying warrants, net of issuance costs, shares Issuance of common stock and accompanying warrants, net of issuance costs, amount Common stock issued for related party patent liabilities, shares Common stock issued for related party patent liabilities, amount Common stock issued for warrant exercise, shares Common stock issued for warrant exercise, amount Balance, shares Balance, amount ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization And Summary Of Significant Accounting Policies LICENSING AGREEMENTS Licensing Agreements RELATED PARTY TRANSACTIONS Related Party Transactions DEBT Debt DERIVATIVE LIABILITIES Derivative Liabilities STOCKBASED COMPENSATION Stock-based Compensation EX-101.CAL 8 celz-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 celz-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 celz-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 11 celz_10qimg1.jpg begin 644 celz_10qimg1.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2022	Nov. 10, 2022
Cover [Abstract]
Entity Registrant Name	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Entity Central Index Key	0001187953
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		14,076,246
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-53500
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	87-0622284
Entity Address Address Line 1	211 E Osborn Road
Entity Address City Or Town	Phoenix
Entity Address State Or Province	AZ
Entity Address Postal Zip Code	85012
City Area Code	480
Local Phone Number	399-2822
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	CELZ
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2022	Dec. 31, 2021
CURRENT ASSETS
Cash	$ 16,969,063	$ 10,723,870
Certificates of deposit	5,021,307	0
Accounts receivable	0	2,485
Inventory	15,894	10,866
Total Current Assets	22,006,264	10,737,221
OTHER ASSETS
Other assets	3,281	3,281
Licenses, net of amortization	458,616	527,679
TOTAL ASSETS	22,468,161	11,268,181
CURRENT LIABILITIES
Accounts payable	327,843	761,862
Accrued expenses	54,920	24,385
Management fee and patent liabilities - related parties	0	250,000
Advances from related party	14,194	14,194
Total Current Liabilities	396,957	1,050,441
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 25,000,000,000 and 6,000,000,000 shares authorized; 14,076,246 and 6,338,872 issued and 14,076,238 and 6,338,864 outstanding at September 30, 2022 and December 31, 2021, respectively	14,077	6,339
Additional paid-in capital	69,653,293	53,879,215
Accumulated deficit	(47,596,166)	(43,667,814)
TOTAL STOCKHOLDERS' EQUITY	22,071,204	10,217,740
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 22,468,161	$ 11,268,181

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
CONDENSED CONSOLIDATED BALANCE SHEETS
Common Stock, Shares Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	25,000,000,000	6,000,000,000
Common Stock, Shares Issued	14,076,246	6,338,872
Common Stock, Shares Outstanding	14,076,238	6,338,864

XML 15 R4.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 55,000	$ 10,000	$ 70,000	$ 20,000
Cost of revenues	16,000	4,000	22,791	8,500
Gross profit	39,000	6,000	47,209	11,500
OPERATING EXPENSES
Research and development	230,940	59,180	900,635	59,180
Selling, general and administrative	805,461	757,235	3,043,946	1,536,479
Amortization of patent costs	23,021	23,021	69,063	69,063
TOTAL EXPENSES	1,059,422	839,436	4,013,644	1,664,722
Operating loss	(1,020,422)	(833,436)	(3,966,435)	(1,653,222)
OTHER INCOME/(EXPENSE)
Interest expense	0	(1,305,273)	0	(1,875,687)
Gain on extinguishment of convertible notes	0	489,157	0	585,601
Change in fair value of derivatives liabilities	0	(194,044)	0	26,030,549
Other income	38,083	0	38,083	0
Total other income (expense)	38,083	(1,010,160)	38,083	24,740,463
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES	(982,339)	(1,843,596)	(3,928,352)	23,087,241
Provision for income taxes	0	0	0	0
NET INCOME (LOSS)	$ (982,339)	$ (1,843,596)	$ (3,928,352)	$ 23,087,241
BASIC NET INCOME (LOSS) PER SHARE	$ (0.07)	$ (0.75)	$ (0.40)	$ 9.98
DILUTED NET INCOME (LOSS) PER SHARE	$ (0.07)	$ (0.75)	$ (0.40)	$ 9.77
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC	14,068,412	2,452,076	9,872,450	2,313,005
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - DILUTED	14,068,412	2,452,076	9,872,450	2,363,145

XML 16 R5.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (3,928,352)	$ 23,087,241
Adjustments to reconcile net income (loss) to net cash from operating activities:
Stock-based compensation	59,584	595,380
Amortization	69,063	69,063
Amortization of debt discounts	0	1,755,104
Change in fair value of derivatives liabilities	0	(26,030,549)
Increase in principal and accrued interest balances due to penalty provision	0	93,821
Gain on extinguishment of convertible notes	0	(585,601)
Changes in assets and liabilities:
Accounts receivable	2,485	0
Inventory	(5,028)	0
Accounts payable	(434,019)	103,626
Accrued expenses	30,535	26,169
Management fee payable	0	(168,700)
Net cash used in operating activities	(4,205,732)	(1,054,446)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of certificates of deposit	(5,021,307)	0
Advance to related party	0	(200,000)
Net cash used in investing activities	(5,021,307)	(200,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock and warrants, net of issuance costs	15,471,775	0
Proceeds from exercise of warrants	457	0
Proceeds from note payable	0	3,887,750
Payments on notes payable	0	(105,000)
Payment of debt issuance costs	0	(443,239)
Payment of deferred offering costs	0	(3,282)
Proceeds from convertible notes payable	0	435,040
Proceeds from sale of preferred stock	0	462,000
Related party advances	0	226,500
Repayment of related party advances	0	(220,000)
Payments to settle convertible notes payable and warrants	0	(705,405)
Net cash provided by financing activities	15,472,232	3,534,364
NET INCREASE IN CASH	6,245,193	2,279,918
BEGINNING CASH BALANCE	10,723,870	98,012
ENDING CASH BALANCE	16,969,063	2,377,930
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	0	9,186
Cash payments for income taxes	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accrued dividends on preferred stock	0	27,725
Warrants issued with notes payable as a service fee	0	2,097,629
Conversion of notes payable, accrued interest and derivative liabilities into common stock	0	13,747,415
Conversion of management fees and patent liability into common stock	250,000	50,000
Discounts on convertible notes payable due to derivative liabilities	0	134,640
Exchange of preferred stock for notes payable	$ 0	$ 572,275

XML 17 R6.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Series A, Preferred Stock	Series B, Preferred Stock	Series C, Preferred Stock
Balance, shares at Dec. 31, 2020		1,537,073			3,000,000
Balance, amount at Dec. 31, 2020	$ (39,803,010)	$ 1,537	$ 22,082,689	$ (61,890,236)	$ 3,000	$ 0	$ 0
Proceeds from sales of preferred stock, shares		4,286				350	150
Proceeds from sales of preferred stock, amount	462,000	$ 4	(4)	0	0	$ 321,000	$ 141,000
Common stock issued for related party management liabilities, shares		89,286
Common stock issued for related party management liabilities, amount	50,000	$ 89	49,911	0	0	0	0
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		789,727
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount	1,383,331	$ 790	1,382,541	0	0	0	0
Relief of derivative liabilities	12,364,084	0	12,364,084	0	0	0	0
Dividends on preferred stock	(27,725)	$ 0	(27,725)	0	0	0	0
Cashless exercise of warrants, shares		37,870
Cashless exercise of warrants, amount	0	$ 38	(38)	0	0	0	0
Warrants issued with notes payable	2,097,629	0	2,097,629	0	0	$ 0	$ 0
Preferred stock redemption, shares						350	150
Preferred stock redemption, amount	(572,275)	0	(110,275)	0	0	$ (321,000)	$ (141,000)
Stock-based compensation	595,380	0	595,380	0	0	0	0
Net income	23,087,241	$ 0	0	23,087,241	$ 0	0	0
Balance, shares at Sep. 30, 2021		2,458,242			3,000,000
Balance, amount at Sep. 30, 2021	(363,345)	$ 2,458	38,434,192	(38,802,995)	$ 3,000	$ 0	$ 0
Balance, shares at Jun. 30, 2021		2,440,614			3,000,000	350	150
Balance, amount at Jun. 30, 2021	(714,453)	$ 2,440	35,777,506	(36,959,399)	$ 3,000	$ 321,000	$ 141,000
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		17,628
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount	153,980	$ 18	153,962	0	0	0	0
Relief of derivative liabilities	138,731	0	138,731	0	0	0	0
Dividends on preferred stock	(6,973)	0	(6,973)	0	0	0	0
Warrants issued with notes payable	2,097,629	0	2,097,629	0	0	$ 0	$ 0
Preferred stock redemption, shares						350	150
Preferred stock redemption, amount	(572,275)	0	(110,275)	0	0	$ (321,000)	$ (141,000)
Stock-based compensation	383,612	0	383,612	0	0	0	0
Net income	(1,843,596)	$ 0	0	(1,843,596)	$ 0	0	0
Balance, shares at Sep. 30, 2021		2,458,242			3,000,000
Balance, amount at Sep. 30, 2021	(363,345)	$ 2,458	38,434,192	(38,802,995)	$ 3,000	0	0
Balance, shares at Dec. 31, 2021		6,338,864
Balance, amount at Dec. 31, 2021	10,217,740	$ 6,339	53,879,215	(43,667,814)	0	0	0
Stock-based compensation	59,584	0	59,584	0	0	0	0
Net income	(3,928,352)	$ 0	0	(3,928,352)	0	0	0
Issuance of common stock and accompanying warrants, net of issuance costs, shares		2,991,669
Issuance of common stock and accompanying warrants, net of issuance costs, amount	15,471,775	$ 2,992	15,468,783	0	0	0	0
Common stock issued for related party patent liabilities, shares		181,818
Common stock issued for related party patent liabilities, amount	250,000	$ 182	249,818	0	0	0	0
Common stock issued for warrant exercise, shares		4,563,887
Common stock issued for warrant exercise, amount	457	$ 4,564	(4,107)	0	0	0	0
Balance, shares at Sep. 30, 2022		14,076,238
Balance, amount at Sep. 30, 2022	22,071,204	$ 14,077	69,653,293	(47,596,166)	0	0	0
Balance, shares at Jun. 30, 2022		13,956,238
Balance, amount at Jun. 30, 2022	23,044,369	$ 13,957	69,644,239	(46,613,827)	0	0	0
Stock-based compensation	9,162	0	9,162	0	0	0	0
Net income	(982,339)	$ 0	0	(982,339)	0	0	0
Common stock issued for warrant exercise, shares		120,000
Common stock issued for warrant exercise, amount	12	$ 120	(108)	0	0	0	0
Balance, shares at Sep. 30, 2022		14,076,238
Balance, amount at Sep. 30, 2022	$ 22,071,204	$ 14,077	$ 69,653,293	$ (47,596,166)	$ 0	$ 0	$ 0

XML 18 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2022

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization And Summary Of Significant Accounting Policies

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Risks and Uncertainties - The Company has a limited operating history and has only recently started to generate revenues from its planned principal operations.

Payments received for which the earnings process is not yet complete are deferred. As of September 30, 2022, the Company had no deferred revenue.

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

	For the Nine- Months Ended September 30, 2021
Weighted average common shares outstanding used in calculating basic earnings per share		2,313,005
Effect of Series B and C preferred stock		-
Effect of warrants		50,140
Effect of convertible notes payable		-
Effect of convertible related party management fee and patent liabilities		-
Weighted average common shares outstanding used in calculating diluted earnings per share		2,363,145

Net income as reported	$	23,087,241
Add - Interest on convertible notes payable		-
Net income available to common stockholders	$	23,087,241

XML 19 R8.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS

9 Months Ended

Sep. 30, 2022

LICENSING AGREEMENTS

Licensing Agreements

NOTE 2 – LICENSING AGREEMENTS

	·	The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.
	·	In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:

	o	$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.
	o	$200,000, upon completion of the IRB clinical trial.
	o	$300,000 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.

In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:

	o	$100,000 upon filing an IND with the FDA.
	o	$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.
	o	$400,000 upon dosing the first patient in a Phase 3 clinical trial.

Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date.

In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.

The following is a roll-forward of the Company’s licensing agreements for the Nine-Months ended September 30, 2022.

	Assets		Accumulated Amortization

Balances at December 31, 2021	$	760,000	$	(232,321	)
Addition of new assets				-
Amortization		-		(69,063	)
Balances at September 30, 2022	$	760,000	$	(301,384	)

XML 20 R9.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2022

RELATED PARTY TRANSACTIONS

Related Party Transactions

NOTE 3 – RELATED PARTY TRANSACTIONS

Management Reimbursement Agreement

Debt Settlement Agreement

Jadi Cell License Agreement

StemSpine Patent Purchase

Insider Loans

XML 21 R10.htm IDEA: XBRL DOCUMENT

DEBT

9 Months Ended

Sep. 30, 2022

DEBT

Debt

NOTE 4 – DEBT

As-of September 30, 2022, the Company had no outstanding loans and there was no loan activity during the Nine-Months ended September 30, 2022.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES

9 Months Ended

Sep. 30, 2022

DERIVATIVE LIABILITIES

Derivative Liabilities

NOTE 5 – DERIVATIVE LIABILITIES

Derivative Liabilities

As-of September 30, 2022, the Company had no outstanding derivative liabilities and there was no derivative activity during the Nine-Months ended September 30, 2022.

XML 23 R12.htm IDEA: XBRL DOCUMENT

STOCKBASED COMPENSATION

9 Months Ended

Sep. 30, 2022

STOCKBASED COMPENSATION

Stock-based Compensation

NOTE 6 – STOCK-BASED COMPENSATION

	Inputs Used

Annual dividend yield	$	-
Expected life (years)		10.0
Risk-free interest rate		0.81	%
Expected volatility		92.95	%
Common stock price	$	1.69

During the Nine-Months ended September 30, 2021, the fair market value of the options was insignificant to the financial statements.

There were no options issued during the Nine-Months ended September 30, 2021.

Option activity for the Nine-Months ended September 30, 2022 consists of the following:

	Stock Options		Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2021		7	$	7,500		4.64
Issued		111,817				-
Exercised		-		-		-
Expired		-		-		-
Outstanding, September 30, 2022		111,824	$	2.16		9.32
Vested, September, 30, 2022		27,961	$	3.57		9.32

XML 24 R13.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY

9 Months Ended

Sep. 30, 2022

STOCKHOLDERS EQUITY

STOCKHOLDERS' EQUITY

NOTE 7 – STOCKHOLDERS’ EQUITY

The Common Warrants have a five-year term, and an exercise price of $2.00 per share. The Pre-Funded Warrants do not expire, and have an exercise price of $0.0001 per share.

The issuances and exercises during the Nine-Months ended September 30, 2022, are as follows:

Outstanding at December 31, 2021		6,604,820
Issuances		20,808,332
Exercises		(4,563,887	)
Outstanding at September 30, 2022		22,849,272
Weighted Average Price at September 30, 2022	$	2.66

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2022

SUBSEQUENT EVENTS

Subsequent Events

NOTE 8 – SUBSEQUENT EVENTS

In accordance with ASC 855, management reviewed all material events through November 15, 2022, for these financial statements. The material subsequent events are as follows:

XML 26 R15.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2022

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization

Use Of Estimates

Basis Of Presentation

Risks And Uncertainties

Risks and Uncertainties - The Company has a limited operating history and has only recently started to generate revenues from its planned principal operations.

Revenue

Payments received for which the earnings process is not yet complete are deferred. As of September 30, 2022, the Company had no deferred revenue.

Concentration Risks

Fair Value Of Financial Instruments

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Basic and Diluted Loss Per Share

	For the Nine- Months Ended September 30, 2021
Weighted average common shares outstanding used in calculating basic earnings per share		2,313,005
Effect of Series B and C preferred stock		-
Effect of warrants		50,140
Effect of convertible notes payable		-
Effect of convertible related party management fee and patent liabilities		-
Weighted average common shares outstanding used in calculating diluted earnings per share		2,363,145

Net income as reported	$	23,087,241
Add - Interest on convertible notes payable		-
Net income available to common stockholders	$	23,087,241

Recent Accounting Pronouncements

XML 27 R16.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2022

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule Of Basic And Diluted Loss Per Share

	For the Nine- Months Ended September 30, 2021
Weighted average common shares outstanding used in calculating basic earnings per share		2,313,005
Effect of Series B and C preferred stock		-
Effect of warrants		50,140
Effect of convertible notes payable		-
Effect of convertible related party management fee and patent liabilities		-
Weighted average common shares outstanding used in calculating diluted earnings per share		2,363,145

Net income as reported	$	23,087,241
Add - Interest on convertible notes payable		-
Net income available to common stockholders	$	23,087,241

XML 28 R17.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS (Tables)

9 Months Ended

Sep. 30, 2022

LICENSING AGREEMENTS

Schedule Of Licensing Agreements

	Assets		Accumulated Amortization

Balances at December 31, 2021	$	760,000	$	(232,321	)
Addition of new assets				-
Amortization		-		(69,063	)
Balances at September 30, 2022	$	760,000	$	(301,384	)

XML 29 R18.htm IDEA: XBRL DOCUMENT

STOCKBASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2022

STOCKBASED COMPENSATION

Schedule Of Warrants

	Inputs Used

Annual dividend yield	$	-
Expected life (years)		10.0
Risk-free interest rate		0.81	%
Expected volatility		92.95	%
Common stock price	$	1.69

Schedule Of Stock Option Activity

	Stock Options		Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2021		7	$	7,500		4.64
Issued		111,817				-
Exercised		-		-		-
Expired		-		-		-
Outstanding, September 30, 2022		111,824	$	2.16		9.32
Vested, September, 30, 2022		27,961	$	3.57		9.32

XML 30 R19.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Tables)

9 Months Ended

Sep. 30, 2022

STOCKHOLDERS EQUITY

Schedule Of issuances and exercises

Outstanding at December 31, 2021		6,604,820
Issuances		20,808,332
Exercises		(4,563,887	)
Outstanding at September 30, 2022		22,849,272
Weighted Average Price at September 30, 2022	$	2.66

XML 31 R20.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Weighted Average Common Shares Outstanding Used In Calculating Basic Earnings Per Share				2,313,005
Effect Of Warrants				50,140
Weighted Average Common Shares Outstanding Used In Calculating Diluted Earnings Per Share	14,068,412	2,452,076	9,872,450	2,363,145
Net Income As Reported				$ 23,087,241
Add - Interest On Convertible Notes Payable				0
Net Income Available To Common Stockholders				$ 23,087,241

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.

+ References + Details

XML 32 R21.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Nov. 10, 2021
Fdic Insured Amount		$ 250,000
Reverse stock split	On November 10, 2021, we effected a 1-for-500 reverse split of our authorized and issued and outstanding shares of common stock
Common shares auhorized	25,000,000,000		6,000,000,000	50,000,000
Options [Member]
Anti-dilutive Securities Excluded From Computation Of Earning Per Share	111,824
Warrants [Member]
Anti-dilutive Securities Excluded From Computation Of Earning Per Share	22,849,272

XML 33 R22.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS (Details)	9 Months Ended
LICENSING AGREEMENTS (Details)	Sep. 30, 2022 USD ($)
Assets
Beginning Balance	$ 760,000
Amortization	0
Ending Balance	760,000
Accumulated Amortization
Accumulated Amortization, Beginning Balance	(232,321)
Addition Of New Assets	0
Amortization Accumulated	(69,063)
Accumulated Amortization, Ending Balance	$ (301,384)

XML 34 R23.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
LICENSING AGREEMENTS (Details Narrative) - USD ($)	Dec. 28, 2020	May 17, 2017	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jan. 31, 2021	Jan. 08, 2021	Sep. 30, 2020	Dec. 12, 2019	Feb. 02, 2016
Company Paid Cmh								$ 50,000	$ 50,000	$ 40,000
Common Stock Issue								89,286	133	84,656	6,667
Common stock value			$ 14,077		$ 14,077		$ 6,339					$ 100,000
Obligation Of The Initial Payment								$ 300,000	$ 300,000	$ 300,000
License Fees	$ 250,000
Cash Payment In Intial Payment											$ 50,000
License Agreement Description	the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
License Agreement Description final	Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty
Restricted Common Stock												$ 431,111
Amortization Expenses					7,479
Carrying Value Of Patent			33,507		$ 33,507
Expiration Period Of Finite-lived Intangible Assets					2025
Expected Amount Of Amortization					$ 9,972
Amortization Expenses			23,021	$ 23,021	69,063	$ 69,063
Option [Member]
Initial Payment											$ 100,000
Creative Medical Health Inc [Member] \| Patents [Member]
Amortization Expenses					7,500
Carrying Value Of Patent			47,500		$ 47,500
Expiration Period Of Finite-lived Intangible Assets					May 19, 2027
Expected Amount Of Amortization					$ 10,000
Initial Payment		$ 100,000
Percentage Of Discount On The Basis Of Recent Trading Price		30
Share Price For Two Or More Consecutive Trading Days		0.01
Creative Medical Health Inc [Member] \| Patents [Member] \| Scenario One [Member]
Payments Upon Signing Agreement With University For The Initiation Of An Irb Clinical Trial		$ 100,000
Payments Upon Completion Of The Irb Clinical Trial		200,000
Payments In The Event Of Commercialization Of Technology		300,000
Creative Medical Health Inc [Member] \| Patents [Member] \| Scenario Two [Member]
Payments Upon Filing An Ind With The Fda		100,000
Payments Upon Dosing Of The First Patient In A Phase 1-2 Clinical Trial		200,000
Payments Upon Dosing Of The First Patient In Phase 3 Clinical Trial		$ 400,000
Stemspine LLC [Member]
Royalty Payment Percentage		5.00%
Non-royalty Sublease Income Percentage.		50.00%
Stemspine LLC [Member] \| Patents [Member]
Amortization Expenses					34,455
Carrying Value Of Patent			167,859		167,859
Expected Amount Of Amortization					46,000
Patent License Agreement [Member]
License Fees					250,000
Amortization Expenses					12,500
Carrying Value Of Patent			212,500		$ 212,500
Expiration Period Of Finite-lived Intangible Assets					2030
Expected Amount Of Amortization					$ 25,000
Multipotent Amniotic Fetal Stem Cells License Agreement [Member] \| Patents [Member]
Carrying Value Of Patent			$ 3,498		$ 3,498
Expiration Period Of Finite-lived Intangible Assets					2026
Expected Amount Of Amortization					$ 1,172
Amortization Expenses					879
Number of share issuance cf common stock to jadi cell					$ 180,180

XML 35 R24.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)		1 Months Ended
	Jan. 12, 2018	May 28, 2021	Dec. 28, 2020	Nov. 17, 2017	May 17, 2017	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Jan. 31, 2021	Jan. 08, 2021	Dec. 12, 2020	Sep. 30, 2020	Dec. 12, 2019
Proceeds From Director		$ 150,000
Debt Interest Rate								5.00%
Company Paid Cmh									$ 50,000	$ 50,000		$ 40,000
Obligation Of The Initial Payment									$ 300,000	300,000		$ 300,000
Cash Payment In Intial Payment													$ 50,000
Common Stock Issued						14,076,246	6,338,872
Management Reimbursement agreement CMH [Member]
Reimbursement of management fees monthly				$ 45,000
StemSpine Patent Purchase [Member]
Company Paid Cmh		$ 50,000								$ 50,000
Obligation Of The Initial Payment						$ 300,000
Common Stock Issued									89,286	133	6,667	84,656
Long-term Purchase Commitment, Amount					$ 100,000
Remaining portion of obligation paid in cash									$ 300,000
Debt Settlement Agreement Timothy Warbington [Member]
Series A Preferred Stock Issued	3,000,000
Cancellation Of Debt	$ 150,000
Preferred Stock Surrender And Exchange Description	Mr. Warbington surrendered the Series A Preferred Stock to the Company in December 2021 immediately prior to the closing of the Company’s public offering in exchange for $150,000 plus 8% interest on such amount from January 2018 until the date of surrender
Jadi Cell License Agreement [Member]
License Fee			$ 250,000
Agreement Description			Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company
Common Stock Issued			181,818

XML 36 R25.htm IDEA: XBRL DOCUMENT

DEBT (Details Narrative)	1 Months Ended		9 Months Ended
DEBT (Details Narrative)	Jun. 21, 2021 USD ($)	May 28, 2021 USD ($)	Sep. 30, 2022 USD ($) integer $ / shares shares	Sep. 30, 2021 USD ($)	Aug. 11, 2021 USD ($)
Debt Conversion, Shares Issued \| shares			789,727
Aggregate principal amount					$ 4,456,176
Aggregate principal amount for Bridge notes					690,000
Financing Fees					$ 758,426
Debt Conversion, Converrted Instrument, Shares Issued \| shares			37,870
Aggregate of outstanding principal, interest and fees				$ 1,383,331
Common Stock Issued For Cashless Warrant Exercise, Shares \| shares			43,167
Unamortized Debt Discount			$ 0
Amortization Of Debt Discount			$ 1,755,104
Initial exercise price \| $ / shares			$ 14.175
Stock issued to common stock \| shares			363,046
Placement agent fee to ROATH			$ 312,750
Proceeds from convertible notes payable			0	$ 435,040
Accredited Investors [Member] \| Convertible Debt [Member]
Amortization Of Debt Discount			$ 443,905
Interest Rate	10.00%	5.00%	8.00%
Debt Instrument, Convertible, Threshold Trading Day \| integer			15
Proceeds from convertible notes payable	$ 100,000		$ 435,040
Convertible notes issued	$ 105,000		$ 498,800
Accredited Investors [Member] \| Convertible Debt [Member] \| Minimum [Member]
Conversion Price, Percentage			60.00%
Accredited Investors [Member] \| Convertible Debt [Member] \| Maximum [Member]
Conversion Price, Percentage			71.00%
CEO [Member]
Advanced received		$ 50,000
Board Member [Member]
Advanced received		$ 150,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
DERIVATIVE LIABILITIES (Details Narrative) - USD ($)	Aug. 30, 2021	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Aggregate principal amount	$ 4,456,176
Initial derivative liabilities			$ 1,077,757
Dividend yield				0.00%
Risk free interest				0.10%
Convertible notes payable				$ 697,602
Fair Value Assumptions, Expected Term			10 years	1 year
Maximum [Member]
Exercise price		$ 0.0248
Stock price granted	$ 0.0806
Expected volatility				98.14%
Minimum [Member]
Exercise price		$ 0.0106
Stock price granted	$ 0.0340
Expected volatility				75.03%

XML 38 R27.htm IDEA: XBRL DOCUMENT

STOCKBASED COMPENSATION (Details) - USD ($)	9 Months Ended
STOCKBASED COMPENSATION (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
STOCKBASED COMPENSATION (Details)
Annual dividend yield	$ 0
Expected life (years)	10 years	1 year
Risk-free interest rate	0.81%
Expected volatility	92.95%
Common stock price	$ 1.69

XML 39 R28.htm IDEA: XBRL DOCUMENT

STOCKBASED COMPENSATION (Details 1) - Option [Member]	9 Months Ended
STOCKBASED COMPENSATION (Details 1) - Option [Member]	Sep. 30, 2022 $ / shares shares
Outstanding at the begining	7
Issued	111,817
Exercised	0
Expired	0
Outstanding at the end	111,824
Vested	27,961
Weighted Average Exercise Price, Outstanding beginning \| $ / shares	$ 7,500
Weighted Average Exercise Price, Exercised \| $ / shares	0
Weighted Average Exercise Price, Expired \| $ / shares	0
Weighted Average Exercise Price, Outstanding ending \| $ / shares	2.16
Weighted Average Exercise Price, Vested \| $ / shares	$ 3.57
Weighted Average Life Remaining, Outstanding beginning	4 years 7 months 20 days
Weighted Average Life Remaining, Outstanding ending	9 years 3 months 25 days
Weighted Average Life Remaining, Vested	9 years 3 months 25 days

XML 40 R29.htm IDEA: XBRL DOCUMENT

STOCKBASED COMPENSATION (Details Narrative) - USD ($)	9 Months Ended
STOCKBASED COMPENSATION (Details Narrative) - USD ($)	Sep. 30, 2022	Sep. 06, 2021
Common stock price	$ 1.69
Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	111,187
Common stock price	$ 1.69
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date
Employee Stock Options [Member] \| Black Scholes Method [Member]
Options vested, value	$ 145,525
Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		600,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details) - Warrants [Member]	9 Months Ended
STOCKHOLDERS EQUITY (Details) - Warrants [Member]	Sep. 30, 2022 $ / shares shares
Outstanding at the begining	6,604,820
Issuances	20,808,332
Exercises	4,563,887
Outstanding at the end	22,849,272
Weighted Average Exercise Price, Outstanding ending \| $ / shares	$ 2.66

XML 42 R31.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)		9 Months Ended
STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	May 03, 2022	Sep. 30, 2022
Amendment description	pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder
Sale of shares of common stock	2,991,669
Pre-Funded Warrants Exercise price		$ 0.0001
Purchase of warrants shares	4,563,887
Purchase of Pre-Funded Warrant and related Common Warrant	15,111,112
Common warrants exercise price		$ 2.00
Combined offering price of Pre-Funded Warrant and related Common Warrant	$ 2.25
Roth Capital Partners [Member]
Paid placement agent fee		$ 1,360,000
Issued warrant to purchase shares of common stock		1,133,333

XML 43 celz_10q_htm.xml IDEA: XBRL DOCUMENT 0001187953 2022-01-01 2022-09-30 0001187953 celz:RothCapitalPartnersMember 2022-01-01 2022-09-30 0001187953 2022-05-03 0001187953 2022-05-01 2022-05-03 0001187953 celz:WarrantsMember 2022-09-30 0001187953 celz:WarrantsMember 2021-12-31 0001187953 celz:BlackScholesMethodMember celz:EmployeeStockOptionssMember 2022-01-01 2022-09-30 0001187953 celz:EmployeeStockOptionssMember 2022-09-30 0001187953 celz:EmployeeStockOptionssMember 2022-01-01 2022-09-30 0001187953 celz:BoardOfDirectorsMember 2021-09-06 0001187953 us-gaap:OptionMember 2022-09-30 0001187953 us-gaap:OptionMember 2022-01-01 2022-09-30 0001187953 us-gaap:OptionMember 2021-12-31 0001187953 srt:MinimumMember 2021-07-01 2021-09-30 0001187953 srt:MaximumMember 2021-01-01 2021-09-30 0001187953 srt:MinimumMember 2021-01-01 2021-09-30 0001187953 srt:MaximumMember 2021-08-01 2021-08-30 0001187953 srt:MinimumMember 2021-08-01 2021-08-30 0001187953 srt:MaximumMember 2021-07-01 2021-09-30 0001187953 2021-08-01 2021-08-30 0001187953 srt:MaximumMember celz:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0001187953 srt:MinimumMember celz:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0001187953 celz:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember 2021-05-01 2021-05-28 0001187953 celz:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember 2021-06-01 2021-06-21 0001187953 celz:BoardMember 2021-05-01 2021-05-28 0001187953 srt:ChiefExecutiveOfficerMember 2021-05-01 2021-05-28 0001187953 celz:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0001187953 2021-08-11 0001187953 celz:JadiCellLicenseAgreementMember 2020-12-28 0001187953 celz:JadiCellLicenseAgreementMember 2020-12-01 2020-12-28 0001187953 celz:DebtSettlementAgreementTimothyWarbingtonMember 2018-01-01 2018-01-12 0001187953 celz:DebtSettlementAgreementTimothyWarbingtonMember 2018-01-12 0001187953 celz:StemSpinePatentPurchaseMember 2017-05-01 2017-05-17 0001187953 celz:StemSpinePatentPurchaseMember 2021-01-31 0001187953 celz:StemSpinePatentPurchaseMember 2020-09-30 0001187953 celz:StemSpinePatentPurchaseMember 2020-12-12 0001187953 celz:StemSpinePatentPurchaseMember 2022-09-30 0001187953 celz:StemSpinePatentPurchaseMember 2021-05-28 0001187953 celz:StemSpinePatentPurchaseMember 2021-01-08 0001187953 celz:ManagementReimbursementAgreementCMHMember 2017-11-01 2017-11-17 0001187953 2021-05-01 2021-05-28 0001187953 celz:StemspineLLCMember 2017-05-01 2017-05-17 0001187953 celz:CreativeMedicalHealthIncMember celz:ScenarioTwoMember us-gaap:PatentsMember 2017-05-01 2017-05-17 0001187953 celz:CreativeMedicalHealthIncMember celz:ScenarioOneMember us-gaap:PatentsMember 2017-05-01 2017-05-17 0001187953 celz:CreativeMedicalHealthIncMember us-gaap:PatentsMember 2017-05-01 2017-05-17 0001187953 us-gaap:OptionMember 2019-12-12 0001187953 celz:CreativeMedicalHealthIncMember us-gaap:PatentsMember 2017-05-17 0001187953 celz:PatentLicenseAgreementMember 2022-09-30 0001187953 celz:StemspineLLCMember us-gaap:PatentsMember 2022-09-30 0001187953 celz:CreativeMedicalHealthIncMember us-gaap:PatentsMember 2022-09-30 0001187953 us-gaap:PatentsMember celz:MultipotentAmnioticFetalStemCellsLicenseAgreementMember 2022-09-30 0001187953 us-gaap:PatentsMember celz:MultipotentAmnioticFetalStemCellsLicenseAgreementMember 2022-01-01 2022-09-30 0001187953 celz:StemspineLLCMember us-gaap:PatentsMember 2022-01-01 2022-09-30 0001187953 celz:CreativeMedicalHealthIncMember us-gaap:PatentsMember 2022-01-01 2022-09-30 0001187953 2020-12-01 2020-12-28 0001187953 celz:PatentLicenseAgreementMember 2022-01-01 2022-09-30 0001187953 2016-02-02 0001187953 2019-12-12 0001187953 2021-01-31 0001187953 2020-09-30 0001187953 2021-01-08 0001187953 2021-11-10 0001187953 celz:WarrantsMember 2022-01-01 2022-09-30 0001187953 celz:OptionsMember 2022-01-01 2022-09-30 0001187953 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001187953 celz:SeriesCPreferredStocksMember 2022-07-01 2022-09-30 0001187953 celz:SeriesBPreferredStocksMember 2022-07-01 2022-09-30 0001187953 celz:SeriesAPreferredStocksMember 2022-07-01 2022-09-30 0001187953 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001187953 2022-06-30 0001187953 us-gaap:RetainedEarningsMember 2022-06-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001187953 celz:SeriesCPreferredStocksMember 2022-06-30 0001187953 celz:SeriesBPreferredStocksMember 2022-06-30 0001187953 celz:SeriesAPreferredStocksMember 2022-06-30 0001187953 us-gaap:CommonStockMember 2022-06-30 0001187953 celz:SeriesCPreferredStocksMember 2022-09-30 0001187953 celz:SeriesBPreferredStocksMember 2022-09-30 0001187953 celz:SeriesAPreferredStocksMember 2022-09-30 0001187953 us-gaap:RetainedEarningsMember 2022-09-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001187953 us-gaap:CommonStockMember 2022-09-30 0001187953 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001187953 celz:SeriesCPreferredStocksMember 2022-01-01 2022-09-30 0001187953 celz:SeriesBPreferredStocksMember 2022-01-01 2022-09-30 0001187953 celz:SeriesAPreferredStocksMember 2022-01-01 2022-09-30 0001187953 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001187953 us-gaap:RetainedEarningsMember 2021-12-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001187953 celz:SeriesCPreferredStocksMember 2021-12-31 0001187953 celz:SeriesBPreferredStocksMember 2021-12-31 0001187953 celz:SeriesAPreferredStocksMember 2021-12-31 0001187953 us-gaap:CommonStockMember 2021-12-31 0001187953 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001187953 celz:SeriesCPreferredStocksMember 2021-07-01 2021-09-30 0001187953 celz:SeriesBPreferredStocksMember 2021-07-01 2021-09-30 0001187953 celz:SeriesAPreferredStocksMember 2021-07-01 2021-09-30 0001187953 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001187953 2021-06-30 0001187953 us-gaap:RetainedEarningsMember 2021-06-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001187953 celz:SeriesCPreferredStocksMember 2021-06-30 0001187953 celz:SeriesBPreferredStocksMember 2021-06-30 0001187953 celz:SeriesAPreferredStocksMember 2021-06-30 0001187953 us-gaap:CommonStockMember 2021-06-30 0001187953 us-gaap:RetainedEarningsMember 2021-09-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001187953 celz:SeriesCPreferredStocksMember 2021-09-30 0001187953 celz:SeriesBPreferredStocksMember 2021-09-30 0001187953 celz:SeriesAPreferredStocksMember 2021-09-30 0001187953 us-gaap:CommonStockMember 2021-09-30 0001187953 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001187953 celz:SeriesCPreferredStocksMember 2021-01-01 2021-09-30 0001187953 celz:SeriesBPreferredStocksMember 2021-01-01 2021-09-30 0001187953 celz:SeriesAPreferredStocksMember 2021-01-01 2021-09-30 0001187953 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001187953 us-gaap:RetainedEarningsMember 2020-12-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001187953 celz:SeriesCPreferredStocksMember 2020-12-31 0001187953 celz:SeriesBPreferredStocksMember 2020-12-31 0001187953 celz:SeriesAPreferredStocksMember 2020-12-31 0001187953 us-gaap:CommonStockMember 2020-12-31 0001187953 2021-09-30 0001187953 2020-12-31 0001187953 2021-01-01 2021-09-30 0001187953 2021-07-01 2021-09-30 0001187953 2022-07-01 2022-09-30 0001187953 2021-12-31 0001187953 2022-09-30 0001187953 2022-11-10 iso4217:USD shares iso4217:USD shares pure celz:integer 0001187953 false --12-31 Q3 2022

0.001

100000

12500

212500

2025

10-Q true 2022-09-30 false 000-53500 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. NV 87-0622284 211 E Osborn Road Phoenix AZ 85012 480 399-2822 Common Stock, par value $0.001 per share CELZ NASDAQ Yes Yes Non-accelerated Filer true false false 14076246

16969063

10723870

5021307

2485

15894

10866

22006264

10737221

3281

458616

527679

22468161

11268181

327843

761862

54920

24385

250000

14194

396957

1050441

0.001

25000000000

6000000000

14076246

6338872

14076238

6338864

14077

6339

69653293

53879215

-47596166

-43667814

22071204

10217740

22468161

11268181

55000

10000

70000

20000

16000

4000

22791

8500

39000

6000

47209

11500

230940

59180

900635

59180

805461

757235

3043946

1536479

23021

69063

1059422

839436

4013644

1664722

-1020422

-833436

-3966435

-1653222

1305273

1875687

0 489157 0 585601 0 -194044 0 26030549

38083

-1010160

38083

24740463

-982339

-1843596

-3928352

23087241

-982339

-1843596

-3928352

23087241

-0.07

-0.75

-0.40

9.98

-0.07

-0.75

-0.40

9.77

14068412

2452076

9872450

2313005

14068412

2452076

9872450

2363145

3928352

-23087241

59584

595380

69063

1755104

26030549

0 93821

585601

-2485

5028

-434019

103626

30535

26169

0 -168700

-4205732

-1054446

5021307

200000

-5021307

-200000

15471775

457

3887750

105000

443239

0 3282

435040

462000

226500

220000

705405

15472232

3534364

6245193

2279918

10723870

98012

16969063

2377930

9186

0 27725 0 2097629 0 13747415 250000 50000 0 134640 0 572275

6338864

6339

53879215

-43667814

10217740

0 0 0 2991669 2992 15468783 0 15471775 0 0 0 181818 182 249818 0 250000 0 0 0 4563887 4564 -4107 0 457 0 0 0 0 59584 0 59584

-3928352

14076238

14077

69653293

-47596166

22071204

13956238

13957

69644239

-46613827

23044369

0 0 0 120000 120 -108 0 12 0 0 0 0 9162 0 9162

-982339

14076238

14077

69653293

-47596166

22071204

3000000

3000

1537073

1537

22082689

-61890236

-39803010

0 350 321000 150 141000 4286 4 -4 0 462000 0 0 0 89286 89 49911 0 50000

789727

790

1382541

1383331

12364084

0 0 0 0 -27725 0 -27725 0 0 0 37870 38 -38 0 0

2097629

350

-321000

150

-141000 0 -110275 0 -572275 0 0 0 0 595380 595380

23087241

3000000

3000

2458242

2458

38434192

-38802995

-363345

3000000

3000

350

321000

150

141000

2440614

2440

35777506

-36959399

-714453

17628

153962

153980

138731

0 0 0 0 -6973 0 -6973

2097629

350

-321000

150

-141000 0 -110275 0 -572275 0 0 0 0 383612 0 383612

-1843596

3000000

3000

2458242

2458

38434192

-38802995

-363345

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization – Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company focused on immunology, urology, orthopedics and neurology using adult stem cell treatments. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly-owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business. CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AmnioStem LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AmnioStem LLC have commenced commercial activities. The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. On October 20, 2022 the Company announced it has produced an allogenic Cell Line called AlloStem™, which includes a Master Cell Bank and a Drug Master File which shall be submitted for FDA registration. The importance of the company creating and developing such assets, as opposed to licensing agreements with third parties, provides further de-risking of an important component to many of our programs, including, but not limited to, the ImmCelz® immunotherapy platform for multiple diseases, OvaStem® for Premature Ovarian Failure, AlloStem™ for Type 1 diabetes, StemSpine® for lower back pain, and IPSCelz ™ inducible pluripotent stem cell program in ongoing development with Greenstone Biosciences. In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began exploring the development of an immunotherapy platform that “supercharges” the patients own immune cells. Secreted factors from AlloStem™ cells are used to “reprogram” the patient’s own immune cells. They are then harvested and injected back into the patient in less than 72 hours. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration. On June 15, 2022, the Company signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the development of a human induced pluripotent stem cell (iPSC) pipeline for the Company's ImmCelz® platform. This project is identified as iPScelzTM. Human iPSc's are genetically reprogrammed to differentiate into a wide array of human cell and tissue types, possess the ability to proliferate almost indefinitely in culture, and represent a single source of cells that could be used to replace those lost to damage or disease. Beyond the therapeutic benefits offered by iPSC, the next generation iPScelzTM pipeline for ImmCelz® will enable the ability for large scale production and sustainability, while helping to reduce long term costs of manufacturing. Use of Estimates – The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.Basis of Presentation - The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. The operations for the nine-month period ended September 30, 2022, are not necessarily indicative of the operating results for the full year. Risks and Uncertainties - The Company has a limited operating history and has only recently started to generate revenues from its planned principal operations.On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company has experienced a reduction in revenues due to the COVID-19 outbreak. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations. The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time consuming and could delay launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing. The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones.On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company has a 180 day grace period, until January 4, 2023, during which the Company may regain compliance if the bid price of our common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. In addition, the Company may be eligible for an additional 180-day grace period if we meet Nasdaq’s initial listing standards (other than with respect to minimum bid price) for The Nasdaq Capital Market. The Company intends to actively monitor the bid price for our common stock between now and January 4, 2023, and will consider available options to regain compliance with Nasdaq’s minimum bid price requirements. However, there can be no assurance that the Company will be able to regain compliance with Nasdaq’s Listing Rules and maintain our Nasdaq listing. The delisting of our shares of common stock from Nasdaq may have a material negative impact on the liquidity of our securities, as well as a material negative impact on our ability to raise capital in the future. Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned. The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer. Payments received for which the earnings process is not yet complete are deferred. As of September 30, 2022, the Company had no deferred revenue. Concentration Risks - The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at two financial institutions. As of September 30, 2022, the Company’s balance exceeded the limit at both institutions. Fair Value of Financial Instrument - The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of September 30, 2022, the Company has no derivative liabilities.Basic and Diluted Loss Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stockholders for the Nine-Months ended September 30, 2021. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">For the Nine-Months Ended September 30,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average common shares outstanding used in calculating basic earnings per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,313,005</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of Series B and C preferred stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,140</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of convertible notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of convertible related party management fee and patent liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average common shares outstanding used in calculating diluted earnings per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,363,145</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net income as reported</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,087,241</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Add - Interest on convertible notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net income available to common stockholders</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">23,087,241</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The Company excluded 7 options and 18 warrants from the computation of diluted net income per share for the Nine-Months ended September 30, 2021 as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period. During the Nine-Months ended September 30, 2022, the Company had 111,824 options and 22,849,272 warrants to purchase shares of common stock which have been excluded from the dilutive net loss per share calculation as their effects are anti-dilutive. On November 10, 2021, we effected a 1-for-500 reverse split of our authorized and issued and outstanding shares of common stock. All share references have been restated for this reverse split to the earliest period presented. As a result of the split, the authorized shares of the Company’s common stock decreased to 50,000,000 shares. Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

Organization – Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company focused on immunology, urology, orthopedics and neurology using adult stem cell treatments. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly-owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business. CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AmnioStem LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AmnioStem LLC have commenced commercial activities. The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. On October 20, 2022 the Company announced it has produced an allogenic Cell Line called AlloStem™, which includes a Master Cell Bank and a Drug Master File which shall be submitted for FDA registration. The importance of the company creating and developing such assets, as opposed to licensing agreements with third parties, provides further de-risking of an important component to many of our programs, including, but not limited to, the ImmCelz® immunotherapy platform for multiple diseases, OvaStem® for Premature Ovarian Failure, AlloStem™ for Type 1 diabetes, StemSpine® for lower back pain, and IPSCelz ™ inducible pluripotent stem cell program in ongoing development with Greenstone Biosciences. In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began exploring the development of an immunotherapy platform that “supercharges” the patients own immune cells. Secreted factors from AlloStem™ cells are used to “reprogram” the patient’s own immune cells. They are then harvested and injected back into the patient in less than 72 hours. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration. On June 15, 2022, the Company signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the development of a human induced pluripotent stem cell (iPSC) pipeline for the Company's ImmCelz® platform. This project is identified as iPScelzTM. Human iPSc's are genetically reprogrammed to differentiate into a wide array of human cell and tissue types, possess the ability to proliferate almost indefinitely in culture, and represent a single source of cells that could be used to replace those lost to damage or disease. Beyond the therapeutic benefits offered by iPSC, the next generation iPScelzTM pipeline for ImmCelz® will enable the ability for large scale production and sustainability, while helping to reduce long term costs of manufacturing.

Use of Estimates – The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation - The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. The operations for the nine-month period ended September 30, 2022, are not necessarily indicative of the operating results for the full year.

Risks and Uncertainties - The Company has a limited operating history and has only recently started to generate revenues from its planned principal operations.On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company has experienced a reduction in revenues due to the COVID-19 outbreak. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations. The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time consuming and could delay launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing. The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones.On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company has a 180 day grace period, until January 4, 2023, during which the Company may regain compliance if the bid price of our common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. In addition, the Company may be eligible for an additional 180-day grace period if we meet Nasdaq’s initial listing standards (other than with respect to minimum bid price) for The Nasdaq Capital Market. The Company intends to actively monitor the bid price for our common stock between now and January 4, 2023, and will consider available options to regain compliance with Nasdaq’s minimum bid price requirements. However, there can be no assurance that the Company will be able to regain compliance with Nasdaq’s Listing Rules and maintain our Nasdaq listing. The delisting of our shares of common stock from Nasdaq may have a material negative impact on the liquidity of our securities, as well as a material negative impact on our ability to raise capital in the future.

Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned. The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer. Payments received for which the earnings process is not yet complete are deferred. As of September 30, 2022, the Company had no deferred revenue.

Concentration Risks - The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at two financial institutions. As of September 30, 2022, the Company’s balance exceeded the limit at both institutions.

250000

Fair Value of Financial Instrument - The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of September 30, 2022, the Company has no derivative liabilities.

Basic and Diluted Loss Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stockholders for the Nine-Months ended September 30, 2021. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">For the Nine-Months Ended September 30,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average common shares outstanding used in calculating basic earnings per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,313,005</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of Series B and C preferred stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,140</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of convertible notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of convertible related party management fee and patent liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average common shares outstanding used in calculating diluted earnings per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,363,145</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net income as reported</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,087,241</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Add - Interest on convertible notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net income available to common stockholders</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">23,087,241</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The Company excluded 7 options and 18 warrants from the computation of diluted net income per share for the Nine-Months ended September 30, 2021 as their exercise prices were in excess of the average closing market price of the Company’s common stock during that period. During the Nine-Months ended September 30, 2022, the Company had 111,824 options and 22,849,272 warrants to purchase shares of common stock which have been excluded from the dilutive net loss per share calculation as their effects are anti-dilutive. On November 10, 2021, we effected a 1-for-500 reverse split of our authorized and issued and outstanding shares of common stock. All share references have been restated for this reverse split to the earliest period presented. As a result of the split, the authorized shares of the Company’s common stock decreased to 50,000,000 shares.

2313005

50140

2363145

23087241

111824

22849272

On November 10, 2021, we effected a 1-for-500 reverse split of our authorized and issued and outstanding shares of common stock

50000000

Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

NOTE 2 – LICENSING AGREEMENTS ED Patent – The Company acquired a patent from CMH, a related company on February 2, 2016, in exchange for 431,111 shares of CMTH restricted common stock valued at $100,000. The patent expires in 2025 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $7,479 was recorded for the Nine-Months ended September 30, 2022 and 2021. As of September 30, 2022, the carrying value of the patent was $33,507. The Company expects to amortize $9,972 annually through 2026 related to the patent costs. Multipotent Amniotic Fetal Stem Cells License Agreement - On August 25, 2016, CMT entered into a License Agreement dated August 25, 2016, with a University. This license agreement grants to CMT the exclusive right to all products derived from a patent for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. The license agreement also permits CMT to grant sublicenses. Under the terms of the license agreement, CMT is required to diligently develop, manufacture, and sell any products licensed under the agreement. CMT paid the University an initial license fee within 30 days of entering into the agreement. CMT is also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments and earned royalties on the net sales of licensed products by CMT or any sub licensee. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sub licensee. As of September 30, 2022, no amounts are currently due to the University. The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $879 was recorded for the Nine-Months ended September 30, 2022 and 2021. As of September 30, 2022, the carrying value of the patent was $3,498. The Company expects to amortize approximately $1,172 annually through 2026 related to the patent costs. Lower Back Patent – The Company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017. As amended, the agreement provides the following: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;">·</td><td style="vertical-align:top;">The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.</td></tr><tr style="height:15px"><td> </td><td>·</td><td style="vertical-align:top;">In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"> </td><td style="width:4%;vertical-align:top;">o </td><td style="vertical-align:top;">$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.</td></tr><tr style="height:15px"><td> </td><td>o </td><td style="vertical-align:top;">$200,000, upon completion of the IRB clinical trial.</td></tr><tr style="height:15px"><td> </td><td>o </td><td style="vertical-align:top;">$300,000 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;">·</td><td style="vertical-align:top;">In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"> </td><td style="width:4%;">o </td><td style="vertical-align:top;">$100,000 upon filing an IND with the FDA.</td></tr><tr style="height:15px"><td> </td><td>o </td><td style="vertical-align:top;">$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.</td></tr><tr style="height:15px"><td> </td><td>o </td><td style="vertical-align:top;">$400,000 upon dosing the first patient in a Phase 3 clinical trial.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;">·</td><td style="vertical-align:top;">Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date.</td></tr><tr style="height:15px"><td> </td><td>·</td><td style="vertical-align:top;">In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.</td></tr></tbody></table>The Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 6,667 shares of common stock on December 12, 2019. On January 8, 2021, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 133 shares of common stock. On September 30, 2020, the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 84,656 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 89,286 shares of common stock. The remaining portion of the $300,000 obligation was paid in cash in 2021. The patent expires on May 19, 2027 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $7,500 was recorded for the nine-month periods ended September 30, 2022 and 2021. As of September 30, 2022, the carrying value of the initial patent license was $47,500. The Company expects to amortize approximately $10000 annually through 2027 related to the patent costs. The Company has elected to amortize the increased obligation from the election to commercialize the StemSpine technology over a ten-year period on a straight-line basis. Amortization expense of $34,455 was recorded for the nine-month periods ended September 30, 2022 and 2021. As of September 30, 2022, the carrying value of the patent was $167,859. The Company expects to amortize approximately $46,000 annually through 2027 related to the patent costs. ImmCelz™ - On December 28, 2020, ImmCelz, Inc. (“ImmCelz”), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a former director of the Company. The Agreement grants to ImmCelz™ the patent rights under U.S. Patent# 9,803,176 B2, “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses”. The contract grants ImmCelz™ access to proprietary process of expanding the master cell bank of Jadi Cell LLC, as currently practiced by Licensor and as documented in standard operating procedures (SOPs) and other written documentation. The terms of the agreement are as follows: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Licensee shall pay Licensor a license fee of $250,000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty”) </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">in one or a series of related transactions, of all or substantially all of the business or assets of Licensee ImmCelz, Inc. (“Sale of Assets”) will result in a one-time ten-percent allocation to the licensor, the Continuing Royalty will be calculated at five percent (5%) of the Net Income of Licensee in any calendar quarter in which the Net Income in such calendar quarter reflects the receipt of any consideration from such Sale of Assets.</td></tr></tbody></table> To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 180,180 shares of common stock to Jadi Cell in February 2022. The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $18,750 were recorded for the nine-month periods ended September 30, 2022 and 2021. As of September 30, 2022, the carrying value of the patent was $206,250. The Company expects to amortize approximately $25,000 annually through 2030 related to the patent costs.The following is a roll-forward of the Company’s licensing agreements for the Nine-Months ended September 30, 2022. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Assets</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">AccumulatedAmortization</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances at December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">760,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(232,321 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Addition of new assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(69,063 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances at September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">760,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(301,384 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 431111 100000 7479

33507

9972

879

3498

1172 2026 100000 100000 200000 300000 100000 200000 400000 30 0.01 0.05 0.50 50000 6667 50000 300000 133 300000 84656 300000 89286 May 19, 2027 7500

47500

10000 34455

167859

46000 250000 the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty 250000 180180 25000 2030 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Assets</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">AccumulatedAmortization</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances at December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">760,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(232,321 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Addition of new assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(69,063 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances at September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">760,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(301,384 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 760000 -232321 0

-69063 760000 -301384

NOTE 3 – RELATED PARTY TRANSACTIONS Management Reimbursement Agreement On November 17, 2017, the Company entered into a Management Reimbursement Agreement with CMH, a related party whose directors and executive officers include the Company’s officers and directors. Pursuant to this agreement, during 2019 and 2020, and until September 16, 2021, the Company reimbursed CMH an aggregate of $45,000 per month for the services of management and consultants employed by CMH (including the Company’s Chief Executive Officer and Chief Financial Officer, and the Company’s former directors Dr. Patel and Dr. Ichim). The agreement provided that at the option of CMH, the reimbursable amounts may be paid from time to time in shares of common stock of the Company at a price equal to a 30% discount to the lowest closing price during the 20 trading days prior to time the notice is given. This agreement was terminated effective September 15, 2021. At September 30, 2021 and 2022, no amounts were owed CMH under this agreement. Debt Settlement Agreement On January 12, 2018, the Company entered into a Debt Settlement Agreement with Timothy Warbington, the Company’s Chief Executive Officer, under which the Company issued 3,000,000 shares of super-voting Series A Preferred Stock to Mr. Warbington in exchange for the cancellation of $150,000 of debt owed by the Company to CMH, which CMH in turn was obligated to pay Mr. Warbington. The Series A Preferred Stock previously provided Mr. Warbington with substantial control over all matters subject to a vote of the Company’s shareholders. Mr. Warbington surrendered the Series A Preferred Stock to the Company in December 2021 immediately prior to the closing of the Company’s public offering in exchange for $150,000 plus 8% interest on such amount from January 2018 until the date of surrender. Jadi Cell License Agreement On December 28, 2020, the Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company. The agreement provides Company with an exclusive, worldwide license to U.S. Patent No. 9,803,176 “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses” and the proprietary process of expanding the master cell bank of Jadi Cell LLC, in the field of enhancing autologous cells. The agreement is described in detail in Note 2 above. To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 181,818 shares of common stock to Jadi Cell in February 2022. StemSpine Patent Purchase The Company acquired U.S. Patent No. 9,598,673 covering the use of various stem cells for the treatment of lower back pain from its affiliate CMH pursuant to a Patent Purchase Agreement dated May 17, 2017, which was amended in November 2017. The inventors of the patent were Thomas Ichim, PhD and Amit Patel, MD, former directors of the Company, and Annette Marleau, PhD. The Patent Purchase Agreement is described in detail in Note 2 above. Pursuant to the Patent Purchase Agreement, the Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 6,667 shares of common stock on December 12, 2020. On January 8, 2021, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 133 shares of common stock. On September 30, 2020, the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 84,656 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 89,286 shares of common stock. The remaining portion of the $300,000 obligation has been paid in cash.Insider Loans On May 28, 2021, Timothy Warbington, who is our CEO and Chairman; and Dr. Amit Patel, who was formerly a director of ours, advanced the Company $50,000 and $150,000 respectively. The two notes were repaid during the quarter ended September 30, 2021, did not have any conversion features, and bore interest at the rate of 5% per annum.

45000 3000000 150000 Mr. Warbington surrendered the Series A Preferred Stock to the Company in December 2021 immediately prior to the closing of the Company’s public offering in exchange for $150,000 plus 8% interest on such amount from January 2018 until the date of surrender Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company 250000

181818

100000

50000 6667 50000 300000 133 40000 300000 84656 50000 300000 89286 300000 50000 150000

0.05

NOTE 4 – DEBT As-of September 30, 2022, the Company had no outstanding loans and there was no loan activity during the Nine-Months ended September 30, 2022. On August 11, 2021, we completed the sale of 15% Original Issue Discount Senior Notes (“Bridge Notes”) in the aggregate principal amount of $4,456,176 to a group of institutional investors (the “Purchasers”). In connection with the sale of the Bridge Notes, holders of our shares of Series B Preferred Stock and Series C Preferred Stock exchanged such preferred stock for additional Bridge Notes in the aggregate principal amount of $690,000. The Bridge Notes were scheduled to mature on February 11, 2022, subject to the requirement that we redeem the Bridge Notes prior to such date with the net proceeds of any future offering of our securities. The notes were redeemed in full as a result of the securities offering on December 7, 2021. The Notes did not bear interest other than upon an event of default, and were not convertible into the Company’s common stock. In addition, the Notes were subject to covenants, events of defaults and other terms and conditions customary in transactions of this nature. The Company amortized the on-issuance discount and financing fees totaling $758,426 to interest expense with respect to these notes. The Company also issued to the purchasers of the Bridge Notes five-year warrants to purchase an aggregate of 363,046 shares of our common stock at an initial exercise price of $14.175 per share, subject to anti-dilution adjustment in the event of future sales of our equity below the then exercise price, stock dividends, stock splits and other specified events. Roth Capital Partners (“Roth”), acted as sole placement agent for the offering. Pursuant to terms of an engagement letter with Roth, the Company paid Roth a placement agent fee in the amount $312,750. The Company also issued Roth a warrant to purchase 20,189 shares of common stock with the same terms as the warrants issued to the Purchasers. During the nine-months ended September 30, 2021, we also issued $498,800 in convertible notes to accredited investors with net proceeds of $435,040, which have since been repaid in full. The notes were to mature during February and July of 2022 and bore interest at a rate of 8%. The notes were convertible into shares of the Company’s common stock at conversion prices ranging from 60% to 71% of the average of the two lowest traded prices or the lowest trade price of the Company’s common stock during the previous 15 trading days preceding the conversion date. The Company amortized the discount due to derivative liabilities and on-issuance discount totaling $443,905 to interest expense with respect to these notes. On May 28, 2021, Mr. Timothy Warbington, who is our CEO and Chairman; and Dr. Amit Patel, who is a director of ours, advanced the company $50,000 and $150,000 respectively. The two notes were repaid during the quarter ended September 30, 2021, did not have any conversion features, and bore interest at the rate of 5% per annum.On June 21, 2021, we issued a $105,000, non-convertible note to an accredited investor with net proceeds of $100,000. The note was repaid during the quarter ended September 30, 2021, did not have any conversion features, and bore interest at the rate of 10% per annum. During the nine-months ended September 30, 2022 there was no amortization to interest expense. During the nine-months ended September 30, 2021, the Company amortized $1,755,104 to interest expense. As of September 30, 2022, total discounts were $0. During the nine-months ended September 30, 2021, the Company issued an aggregate of 789,727 shares upon the conversion of $1,383,331 of outstanding principal, interest and fees on outstanding notes, and 37,870 shares upon the cashless exercise of 43,167 warrants.

4456176 690000

758426

363046 14.175 312750

498800

435040

0.08

0.60

0.71

443905

50000

150000

0.05

105000

100000

0.10 1755104

789727 1383331 37870 43167

NOTE 5 – DERIVATIVE LIABILITIES Derivative Liabilities As-of September 30, 2022, the Company had no outstanding derivative liabilities and there was no derivative activity during the Nine-Months ended September 30, 2022. In connection with convertible notes payable, the Company records derivative liabilities for the conversion feature. The derivative liabilities are valued on the date the convertible note payable become convertible and revalued at each reporting period. During the nine-months ended September 30, 2021, the Company recorded initial derivative liabilities of $1,077,757 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of $0.0106 to $0.0248 our stock price on the date of grant of $0.0340 to $0.0806, expected dividend yield of 0%, expected volatility of 75.03% to 98.14%, risk free interest rate of 0.10% and expected terms of 1.0 year. Upon initial valuation, the derivative liabilities exceeded the face values certain of the convertible notes payable by approximately $697,602, which was recorded as a day one loss in derivative liability. In August 2021, we completed the sale of 15% Original Issue Discount Senior Notes (“Bridge Notes”) in the aggregate principal amount of $4,456,176 to a group of institutional investors (the “Purchasers”). A portion of the proceeds were used to repay the principal, accrued interest, pre-payment fees and other premiums of all the outstanding convertible notes as well as all previously outstanding warrants with re-pricing and anti-dilutive features. The result was $0 in derivative liabilities as-of the period ended September 30, 2021.

1077757 0.0106 0.0248 0.0340 0.0806 0 0.7503 0.9814

0.0010

P1Y

697602 4456176 NOTE 6 – STOCK-BASED COMPENSATION On September 6, 2021, the Company’s Board of Directors and holders of a majority of the voting power of the Company’s stockholders approved the Company’s 2021 Equity Incentive Plan (the “2021 Plan”), and reserved 600,000 shares of common stock for the issuance of awards thereunder. The 2021 Plan provides for the granting to our employees, officers, directors, consultants and advisors of performance awards payable in shares of common stock, stock options (non-statutory and incentive), restricted stock awards, stock appreciation rights (“SARs”), restricted share units (“RSUs”) and other stock-based awards. The purpose of the 2021 Plan is to secure for the Company and its stockholders the benefits arising from capital stock ownership by eligible participants who are expected to contribute to the Company’s future growth and success. During the Nine-Months ended September 30, 2022, Messrs. Warbington and Dickerson received 10-year options to purchase an aggregate of 111,187 shares of common stock with an exercise price of $1.69. The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date. The value of the options was determined to be $145,525 based upon the Black-Scholes method, see variables used below. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Inputs Used</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Annual dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected life (years)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.81</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92.95</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Common stock price</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.69</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>During the Nine-Months ended September 30, 2021, the fair market value of the options was insignificant to the financial statements. Since the expected life of the options was greater than the Company’s historical stock information available, the Company determined the expected volatility based on price fluctuations of comparable public companies. There were no options issued during the Nine-Months ended September 30, 2021. Option activity for the Nine-Months ended September 30, 2022 consists of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Stock Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Life Remaining</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,500</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4.64</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issued</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">111,817</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">111,824</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.16</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9.32</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested, September, 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">27,961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.57</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9.32</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

600000

P10Y

111187

1.69

The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date

145525 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Inputs Used</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Annual dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected life (years)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.81</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92.95</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Common stock price</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.69</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 0

P10Y

0.0081

0.9295

1.69

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Stock Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Life Remaining</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,500</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4.64</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issued</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">111,817</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">111,824</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.16</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9.32</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested, September, 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">27,961</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.57</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9.32</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

7500

P4Y7M20D

111817

111824

2.16

P9Y3M25D

27961

3.57

P9Y3M25D

NOTE 7 – STOCKHOLDERS’ EQUITY On May 3, 2022, the “Company” completed the sale of (i) 2,991,669 shares of common stock, and pre-funded warrants to purchase 4,563,887 shares of common stock (the “Pre-Funded Warrants”), and (ii) accompanying warrants to purchase 15,111,112 shares of common stock (the “Common Warrants”), at a combined offering price of $2.25 per share of common stock/Pre-Funded Warrant and related Common Warrant, to a group of institutional investors (the “Purchasers”), pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder. The Common Warrants have a five-year term, and an exercise price of $2.00 per share. The Pre-Funded Warrants do not expire, and have an exercise price of $0.0001 per share. The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return. Roth Capital Partners (“Roth”), acted as sole placement agent for the offering. The Company paid Roth a placement agent fee in the amount $1,360,000, and issued Roth a warrant to purchase 1,133,333 shares of Common Stock with the same terms as the Common Warrants issued to the Purchasers. The issuances and exercises during the Nine-Months ended September 30, 2022, are as follows: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding at December 31, 2021</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">6,604,820</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">20,808,332</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">(4,563,887 </td><td style="width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding at September 30, 2022</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">22,849,272</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted Average Price at September 30, 2022</td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;">2.66</td><td style="width:1%;"> </td></tr></tbody></table>

2991669

4563887 15111112 2.25 pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder 2.00 0.0001 1360000 1133333 <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding at December 31, 2021</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">6,604,820</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">20,808,332</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">(4,563,887 </td><td style="width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding at September 30, 2022</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;">22,849,272</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted Average Price at September 30, 2022</td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;">2.66</td><td style="width:1%;"> </td></tr></tbody></table>

6604820

20808332

4563887

22849272

2.66

NOTE 8 – SUBSEQUENT EVENTS In accordance with ASC 855, management reviewed all material events through November 15, 2022, for these financial statements. The material subsequent events are as follows: On October 20, 2022 the Company announced it has produced an allogenic Cell Line called AlloStem™, which includes a Master Cell Bank and a Drug Master File which shall be submitted for FDA registration. The importance of the company creating and developing such assets, as opposed to licensing agreements with third parties, provides further de-risking of an important component to many of our programs, including, but not limited to, the ImmCelz® immunotherapy platform for multiple diseases, OvaStem® for Premature Ovarian Failure, AlloStem™ for Type 1 diabetes, StemSpine® for lower back pain, and IPSCelz ™ inducible pluripotent stem cell program in ongoing development with Greenstone Biosciences. On November 3, 2022 the Company announced he U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application, enabling the Company to proceed with initiating a clinical trial for Type 1 Diabetes using AlloStem™ AlloStem™ leverages a unique approach to harnessing the power of Perinatal Tissue Derived Cells® (PRDC) to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, and large-scale clinical expansion. The primary objective of the study (CELZ-201) is to evaluate AlloStem™ in patients with newly diagnosed Type 1 Diabetes. Patient recruitment is expected to begin in Q1 2023 with trial commencement updates to follow.

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 45 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 134 258 1 false 30 0 false 5 false false R1.htm 000001 - Document - Cover Sheet http://celz.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://celz.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://celz.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statements 6 false false R7.htm 000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 000008 - Disclosure - LICENSING AGREEMENTS Sheet http://celz.com/role/LicensingAgreements LICENSING AGREEMENTS Notes 8 false false R9.htm 000009 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://celz.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 9 false false R10.htm 000010 - Disclosure - DEBT Sheet http://celz.com/role/DEBT DEBT Notes 10 false false R11.htm 000011 - Disclosure - DERIVATIVE LIABILITIES Sheet http://celz.com/role/DerivativeLiabilities DERIVATIVE LIABILITIES Notes 11 false false R12.htm 000012 - Disclosure - STOCKBASED COMPENSATION Sheet http://celz.com/role/StockbasedCompensation STOCKBASED COMPENSATION Notes 12 false false R13.htm 000013 - Disclosure - STOCKHOLDERS EQUITY Sheet http://celz.com/role/StockholdersEquity STOCKHOLDERS EQUITY Notes 13 false false R14.htm 000014 - Disclosure - SUBSEQUENT EVENTS Sheet http://celz.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 14 false false R15.htm 000015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 15 false false R16.htm 000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 16 false false R17.htm 000017 - Disclosure - LICENSING AGREEMENTS (Tables) Sheet http://celz.com/role/LicensingAgreementsTables LICENSING AGREEMENTS (Tables) Tables http://celz.com/role/LicensingAgreements 17 false false R18.htm 000018 - Disclosure - STOCKBASED COMPENSATION (Tables) Sheet http://celz.com/role/StockbasedCompensationTables STOCKBASED COMPENSATION (Tables) Tables http://celz.com/role/StockbasedCompensation 18 false false R19.htm 000019 - Disclosure - STOCKHOLDERS EQUITY (Tables) Sheet http://celz.com/role/StockholdersEquityTables STOCKHOLDERS EQUITY (Tables) Tables http://celz.com/role/StockholdersEquity 19 false false R20.htm 000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 20 false false R21.htm 000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 000022 - Disclosure - LICENSING AGREEMENTS (Details) Sheet http://celz.com/role/LicensingAgreementsDetails LICENSING AGREEMENTS (Details) Details http://celz.com/role/LicensingAgreementsTables 22 false false R23.htm 000023 - Disclosure - LICENSING AGREEMENTS (Details Narrative) Sheet http://celz.com/role/LicensingAgreementsDetailsNarrative LICENSING AGREEMENTS (Details Narrative) Details http://celz.com/role/LicensingAgreementsTables 23 false false R24.htm 000024 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://celz.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://celz.com/role/RelatedPartyTransactions 24 false false R25.htm 000025 - Disclosure - DEBT (Details Narrative) Sheet http://celz.com/role/DebtDetailsNarrative DEBT (Details Narrative) Details http://celz.com/role/DEBT 25 false false R26.htm 000026 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) Sheet http://celz.com/role/DerivativeLiabilitiesDetailsNarrative DERIVATIVE LIABILITIES (Details Narrative) Details http://celz.com/role/DerivativeLiabilities 26 false false R27.htm 000027 - Disclosure - STOCKBASED COMPENSATION (Details) Sheet http://celz.com/role/StockbasedCompensationDetails STOCKBASED COMPENSATION (Details) Details http://celz.com/role/StockbasedCompensationTables 27 false false R28.htm 000028 - Disclosure - STOCKBASED COMPENSATION (Details 1) Sheet http://celz.com/role/StockbasedCompensationDetails1 STOCKBASED COMPENSATION (Details 1) Details http://celz.com/role/StockbasedCompensationTables 28 false false R29.htm 000029 - Disclosure - STOCKBASED COMPENSATION (Details Narrative) Sheet http://celz.com/role/StockbasedCompensationDetailsNarrative STOCKBASED COMPENSATION (Details Narrative) Details http://celz.com/role/StockbasedCompensationTables 29 false false R30.htm 000030 - Disclosure - STOCKHOLDERS EQUITY (Details) Sheet http://celz.com/role/StockholdersEquityDetails STOCKHOLDERS EQUITY (Details) Details http://celz.com/role/StockholdersEquityTables 30 false false R31.htm 000031 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) Sheet http://celz.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS EQUITY (Details Narrative) Details http://celz.com/role/StockholdersEquityTables 31 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: celz:AmortizationExpenses, celz:ExpirationPeriodOfFiniteLivedIntangibleAssets, us-gaap:CommonStockNoParValue, us-gaap:CommonStockValue, us-gaap:OtherIntangibleAssetsNet, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod, us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised - celz_10q.htm 1 celz_10q.htm celz-20220930.xsd celz-20220930_cal.xml celz-20220930_def.xml celz-20220930_lab.xml celz-20220930_pre.xml celz_ex311.htm celz_ex312.htm celz_ex321.htm celz_ex322.htm celz_10qimg1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 50 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "celz_10q.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 134, "dts": { "calculationLink": { "local": [ "celz-20220930_cal.xml" ] }, "definitionLink": { "local": [ "celz-20220930_def.xml" ] }, "inline": { "local": [ "celz_10q.htm" ] }, "labelLink": { "local": [ "celz-20220930_lab.xml" ] }, "presentationLink": { "local": [ "celz-20220930_pre.xml" ] }, "schema": { "local": [ "celz-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 351, "entityCount": 1, "hidden": { "http://celz.com/20220930": 2, "http://fasb.org/us-gaap/2022": 5, "http://xbrl.sec.gov/dei/2022": 5, "total": 12 }, "keyCustom": 103, "keyStandard": 155, "memberCustom": 21, "memberStandard": 9, "nsprefix": "celz", "nsuri": "http://celz.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://celz.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - DEBT", "role": "http://celz.com/role/DEBT", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - DERIVATIVE LIABILITIES", "role": "http://celz.com/role/DerivativeLiabilities", "shortName": "DERIVATIVE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:DisclosureOfCompensationRelatedCostsShareBasedPaymentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - STOCKBASED COMPENSATION", "role": "http://celz.com/role/StockbasedCompensation", "shortName": "STOCKBASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:DisclosureOfCompensationRelatedCostsShareBasedPaymentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - STOCKHOLDERS EQUITY", "role": "http://celz.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - SUBSEQUENT EVENTS", "role": "http://celz.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:ScheduleOfLicensingAgreementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - LICENSING AGREEMENTS (Tables)", "role": "http://celz.com/role/LicensingAgreementsTables", "shortName": "LICENSING AGREEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:ScheduleOfLicensingAgreementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "celz:DisclosureOfCompensationRelatedCostsShareBasedPaymentsDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:ScheduleValueOfOptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - STOCKBASED COMPENSATION (Tables)", "role": "http://celz.com/role/StockbasedCompensationTables", "shortName": "STOCKBASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "celz:DisclosureOfCompensationRelatedCostsShareBasedPaymentsDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:ScheduleValueOfOptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:ScheduleOfIssuancesAndExercisesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - STOCKHOLDERS EQUITY (Tables)", "role": "http://celz.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:ScheduleOfIssuancesAndExercisesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://celz.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "celz:WeightedAverageCommonSharesOutstandingUsedInCalculatingBasicEarningsPerShare", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "celz:WeightedAverageCommonSharesOutstandingUsedInCalculatingBasicEarningsPerShare", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "celz:ConcentrationRiskPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "celz:ConcentrationRiskPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "celz:ScheduleOfLicensingAgreementsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "celz:BeginningBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - LICENSING AGREEMENTS (Details)", "role": "http://celz.com/role/LicensingAgreementsDetails", "shortName": "LICENSING AGREEMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "celz:ScheduleOfLicensingAgreementsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "celz:BeginningBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2021-01-31", "decimals": "0", "first": true, "lang": null, "name": "celz:CompanyPaid", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - LICENSING AGREEMENTS (Details Narrative)", "role": "http://celz.com/role/LicensingAgreementsDetailsNarrative", "shortName": "LICENSING AGREEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2021-01-31", "decimals": "0", "lang": null, "name": "celz:CommonStockIssueShare", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2021-05-01to2021-05-28", "decimals": "0", "first": true, "lang": null, "name": "celz:ProceedsFromDirector", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2021-05-01to2021-05-28", "decimals": "0", "first": true, "lang": null, "name": "celz:ProceedsFromDirector", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "celz:DebtConversionSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - DEBT (Details Narrative)", "role": "http://celz.com/role/DebtDetailsNarrative", "shortName": "DEBT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "celz:DebtConversionSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2021-08-01to2021-08-30", "decimals": "0", "first": true, "lang": null, "name": "celz:AggregatePrincipalAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative)", "role": "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative", "shortName": "DERIVATIVE LIABILITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2021-08-01to2021-08-30", "decimals": "0", "first": true, "lang": null, "name": "celz:AggregatePrincipalAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "celz:ScheduleValueOfOptionsTableTextBlock", "celz:DisclosureOfCompensationRelatedCostsShareBasedPaymentsDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "celz:AnnualDividendYield", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - STOCKBASED COMPENSATION (Details)", "role": "http://celz.com/role/StockbasedCompensationDetails", "shortName": "STOCKBASED COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "celz:ScheduleValueOfOptionsTableTextBlock", "celz:DisclosureOfCompensationRelatedCostsShareBasedPaymentsDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "celz:AnnualDividendYield", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_OptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - STOCKBASED COMPENSATION (Details 1)", "role": "http://celz.com/role/StockbasedCompensationDetails1", "shortName": "STOCKBASED COMPENSATION (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_OptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "celz:ScheduleValueOfOptionsTableTextBlock", "celz:DisclosureOfCompensationRelatedCostsShareBasedPaymentsDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - STOCKBASED COMPENSATION (Details Narrative)", "role": "http://celz.com/role/StockbasedCompensationDetailsNarrative", "shortName": "STOCKBASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "celz:DisclosureOfCompensationRelatedCostsShareBasedPaymentsDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30_celz_EmployeeStockOptionssMember", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://celz.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "celz:ScheduleOfIssuancesAndExercisesTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2021-12-31_celz_WarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - STOCKHOLDERS EQUITY (Details)", "role": "http://celz.com/role/StockholdersEquityDetails", "shortName": "STOCKHOLDERS EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "celz:ScheduleOfIssuancesAndExercisesTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2021-12-31_celz_WarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-05-01to2022-05-03", "decimals": null, "first": true, "lang": "en-US", "name": "celz:DescriptionOfAmendment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)", "role": "http://celz.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-05-01to2022-05-03", "decimals": null, "first": true, "lang": "en-US", "name": "celz:DescriptionOfAmendment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-07-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "role": "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:LicensingAgreementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - LICENSING AGREEMENTS", "role": "http://celz.com/role/LicensingAgreements", "shortName": "LICENSING AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:LicensingAgreementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://celz.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 30, "tag": { "celz_AccreditedInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accredited Investors [Member]" } } }, "localname": "AccreditedInvestorsMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_AccruedDividendsOnPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued dividends on preferred stock" } } }, "localname": "AccruedDividendsOnPreferredStock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "celz_AccumulatedAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortization Accumulated" } } }, "localname": "AccumulatedAmortization", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "celz_AccumulatedAmortizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Amortization" } } }, "localname": "AccumulatedAmortizationAbstract", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "celz_AccumulatedAmortizationAdditionOfNewAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Addition Of New Assets" } } }, "localname": "AccumulatedAmortizationAdditionOfNewAssets", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "celz_AccumulatedAmortizationBeginningBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accumulated Amortization, Beginning Balance" } } }, "localname": "AccumulatedAmortizationBeginningBalance", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "celz_AccumulatedAmortizationEndingBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accumulated Amortization, Ending Balance" } } }, "localname": "AccumulatedAmortizationEndingBalance", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "celz_AggregateOfOutstandingPrincipalInterestAndFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate of outstanding principal, interest and fees" } } }, "localname": "AggregateOfOutstandingPrincipalInterestAndFees", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_AggregatePrincipalAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Aggregate principal amount]", "verboseLabel": "Aggregate principal amount" } } }, "localname": "AggregatePrincipalAmount1", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_AggregatePrincipalAmount2": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate principal amount" } } }, "localname": "AggregatePrincipalAmount2", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_AggregatePrincipalAmountForBridgeNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate principal amount for Bridge notes" } } }, "localname": "AggregatePrincipalAmountForBridgeNotes", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_AgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement Description" } } }, "localname": "AgreementDescription", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_AmortizationExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortization Expenses" } } }, "localname": "AmortizationExpenses", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_AmortizationOfDebtDiscounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortization Of Debt Discount" } } }, "localname": "AmortizationOfDebtDiscounts", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_AnnualDividendYield": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Annual dividend yield" } } }, "localname": "AnnualDividendYield", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "celz_AssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetAbstract", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "celz_BeginningBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Beginning Balance" } } }, "localname": "BeginningBalance", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "celz_BlackScholesMethodMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Black Scholes Method [Member]" } } }, "localname": "BlackScholesMethodMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_BoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board Member [Member]" } } }, "localname": "BoardMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_CancellationOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cancellation Of Debt" } } }, "localname": "CancellationOfDebt", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_CashPaymentInIntialPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash Payment In Intial Payment", "verboseLabel": "Cash Payment In Intial Payment" } } }, "localname": "CashPaymentInIntialPayment", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_CashlessExerciseOfWarrantsAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cashless exercise of warrants, amount" } } }, "localname": "CashlessExerciseOfWarrantsAmount", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_CashlessExerciseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cashless exercise of warrants, shares" } } }, "localname": "CashlessExerciseOfWarrantsShares", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "celz_ChangeInFairValueOfDerivativesLiabilities": { "auth_ref": [], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 10.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Change in fair value of derivatives liabilities" } } }, "localname": "ChangeInFairValueOfDerivativesLiabilities", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "celz_CombinedOfferingPriceOfPreFundedWarrantAndRelatedCommonWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Combined offering price of Pre-Funded Warrant and related Common Warrant" } } }, "localname": "CombinedOfferingPriceOfPreFundedWarrantAndRelatedCommonWarrant", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "celz_CommonStockIssueShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Issue" } } }, "localname": "CommonStockIssueShare", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_CommonStockIssued1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Issued" } } }, "localname": "CommonStockIssued1", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_CommonStockIssuedForCashlessWarrantExerciseShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Issued For Cashless Warrant Exercise, Shares" } } }, "localname": "CommonStockIssuedForCashlessWarrantExerciseShares", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_CommonStockIssuedForRelatedPartyManagementLiabilitiesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for related party management liabilities, amount" } } }, "localname": "CommonStockIssuedForRelatedPartyManagementLiabilitiesAmount", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_CommonStockIssuedForRelatedPartyManagementLiabilitiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for related party management liabilities, shares" } } }, "localname": "CommonStockIssuedForRelatedPartyManagementLiabilitiesShares", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "celz_CommonStockIssuedForRelatedPartyPatentLiabilitiesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for related party patent liabilities, amount" } } }, "localname": "CommonStockIssuedForRelatedPartyPatentLiabilitiesAmount", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_CommonStockIssuedForRelatedPartyPatentLiabilitiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for related party patent liabilities, shares" } } }, "localname": "CommonStockIssuedForRelatedPartyPatentLiabilitiesShares", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "celz_CommonStockIssuedForWarrantExerciseAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for warrant exercise, amount" } } }, "localname": "CommonStockIssuedForWarrantExerciseAmount", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_CommonStockIssuedForWarrantExerciseShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for warrant exercise, shares" } } }, "localname": "CommonStockIssuedForWarrantExerciseShares", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "celz_CommonWarrantsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common warrants exercise price" } } }, "localname": "CommonWarrantsExercisePrice", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "celz_CompanyPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Company Paid Cmh", "verboseLabel": "Company Paid Cmh" } } }, "localname": "CompanyPaid", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_ConcentrationRiskPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentration Risks" } } }, "localname": "ConcentrationRiskPolicyTextBlock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "celz_ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of management fees and patent liability into common stock" } } }, "localname": "ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "celz_ConversionOfNotesPayableAccruedInterestAndDerivativeLiabilitiesIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of notes payable, accrued interest and derivative liabilities into common stock" } } }, "localname": "ConversionOfNotesPayableAccruedInterestAndDerivativeLiabilitiesIntoCommonStock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "celz_ConvertibleNotesPayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible notes payable" } } }, "localname": "ConvertibleNotesPayables", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_CreativeMedicalHealthIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Creative Medical Health Inc [Member]" } } }, "localname": "CreativeMedicalHealthIncMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_DebtConversionConverrtedInstrumentSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converrted Instrument, Shares Issued" } } }, "localname": "DebtConversionConverrtedInstrumentSharesIssued", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_DebtConversionSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Conversion, Shares Issued" } } }, "localname": "DebtConversionSharesIssued", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_DebtSettlementAgreementTimothyWarbingtonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Settlement Agreement Timothy Warbington [Member]" } } }, "localname": "DebtSettlementAgreementTimothyWarbingtonMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_DescriptionOfAmendment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amendment description" } } }, "localname": "DescriptionOfAmendment", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_DisclosureOfCompensationRelatedCostsShareBasedPaymentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsDisclosureTextBlock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockbasedCompensation" ], "xbrltype": "textBlockItemType" }, "celz_DiscountsOnConvertibleNotesPayableDueToDerivativeLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Discounts on convertible notes payable due to derivative liabilities" } } }, "localname": "DiscountsOnConvertibleNotesPayableDueToDerivativeLiabilities", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "celz_DividendYield": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend yield" } } }, "localname": "DividendYield", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "celz_DividendsOnPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Dividends on preferred stock" } } }, "localname": "DividendsOnPreferredStock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_EffectOfSeriesBAndCPreferredStockShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effect Of Series B And C Preferred Stock" } } }, "localname": "EffectOfSeriesBAndCPreferredStockShare", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "celz_EmployeeStockOptionssMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Stock Options [Member]" } } }, "localname": "EmployeeStockOptionssMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_EndingBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Ending Balance" } } }, "localname": "EndingBalance", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "celz_ExchangeOfPreferredStockForNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Exchange of preferred stock for notes payable" } } }, "localname": "ExchangeOfPreferredStockForNotesPayable", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "celz_ExpectedAmountOfAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Expected Amount Of Amortization" } } }, "localname": "ExpectedAmountOfAmortization", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_ExpectedAmountOfAmortization1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Expected Amount Of Amortization]", "verboseLabel": "Expected Amount Of Amortization" } } }, "localname": "ExpectedAmountOfAmortization1", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_ExpectedVolatility": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected volatility" } } }, "localname": "ExpectedVolatility", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "celz_ExpirationPeriodOfFiniteLivedIntangibleAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expiration Period Of Finite-lived Intangible Assets" } } }, "localname": "ExpirationPeriodOfFiniteLivedIntangibleAssets", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_GainOnExtinguishmentOfConvertibleNotes": { "auth_ref": [], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 11.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gain on extinguishment of convertible notes" } } }, "localname": "GainOnExtinguishmentOfConvertibleNotes", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "celz_IncreaseDecreaseInManagementFeePayable": { "auth_ref": [], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Management fee payable" } } }, "localname": "IncreaseDecreaseInManagementFeePayable", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "celz_IncreaseInPrincipalAndAccruedInterestBalancesDueToPenaltyProvision": { "auth_ref": [], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Increase in principal and accrued interest balances due to penalty provision" } } }, "localname": "IncreaseInPrincipalAndAccruedInterestBalancesDueToPenaltyProvision", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "celz_IncrementalCommonSharesAttributableToDilutiveEffectOfConvertibleRelatedPartyManagementFeeAndPatentLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effect Of Convertible Related Party Management Fee And Patent Liabilities" } } }, "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfConvertibleRelatedPartyManagementFeeAndPatentLiabilities", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "celz_InitialDerivativeLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Initial derivative liabilities" } } }, "localname": "InitialDerivativeLiabilities", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_InitialExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial exercise price" } } }, "localname": "InitialExercisePrice", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "perShareItemType" }, "celz_InitialPaymentsToAcquireIntangibleAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Initial Payment" } } }, "localname": "InitialPaymentsToAcquireIntangibleAssets", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_InterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Rate" } } }, "localname": "InterestRate", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "celz_IssuanceOfCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock and accompanying warrants, net of issuance costs, amount" } } }, "localname": "IssuanceOfCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsAmount", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_IssuanceOfCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock and accompanying warrants, net of issuance costs, shares" } } }, "localname": "IssuanceOfCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsShares", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "celz_IssuedWarrantToPurchaseSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued warrant to purchase shares of common stock" } } }, "localname": "IssuedWarrantToPurchaseSharesOfCommonStock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_JadiCellLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jadi Cell License Agreement [Member]" } } }, "localname": "JadiCellLicenseAgreementMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_LicenseAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreement Description" } } }, "localname": "LicenseAgreementDescription", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_LicenseAgreementDescriptionFinal": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreement Description final" } } }, "localname": "LicenseAgreementDescriptionFinal", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_LicenseFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "License Fees" } } }, "localname": "LicenseFees", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_Licensefee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "License Fee" } } }, "localname": "Licensefee", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_LicensingAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LICENSING AGREEMENTS" } } }, "localname": "LicensingAgreementsAbstract", "nsuri": "http://celz.com/20220930", "xbrltype": "stringItemType" }, "celz_LicensingAgreementsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Licensing Agreements" } } }, "localname": "LicensingAgreementsDisclosureTextBlock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreements" ], "xbrltype": "textBlockItemType" }, "celz_ManagementReimbursementAgreementCMHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management Reimbursement agreement CMH [Member]" } } }, "localname": "ManagementReimbursementAgreementCMHMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_MultipotentAmnioticFetalStemCellsLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Multipotent Amniotic Fetal Stem Cells License Agreement [Member]" } } }, "localname": "MultipotentAmnioticFetalStemCellsLicenseAgreementMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_NonroyaltySubleaseIncomePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-royalty Sublease Income Percentage." } } }, "localname": "NonroyaltySubleaseIncomePercentage", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "celz_NumberOfShareIssuanceOfCommonStockToJadiCell": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Number of share issuance cf common stock to jadi cell" } } }, "localname": "NumberOfShareIssuanceOfCommonStockToJadiCell", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_ObligationOfTheInitialPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Obligation Of The Initial Payment", "verboseLabel": "Obligation Of The Initial Payment" } } }, "localname": "ObligationOfTheInitialPayment", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_OptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options [Member]" } } }, "localname": "OptionsMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_PaidPlacementAgentFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Paid placement agent fee" } } }, "localname": "PaidPlacementAgentFee", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PatentLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patent License Agreement [Member]" } } }, "localname": "PatentLicenseAgreementMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_PaymentOfDeferredOfferingCosts": { "auth_ref": [], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Payment of deferred offering costs]", "negatedLabel": "Payment of deferred offering costs" } } }, "localname": "PaymentOfDeferredOfferingCosts", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "celz_PaymentsInTheEventOfCommercializationOfTechnology": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments In The Event Of Commercialization Of Technology" } } }, "localname": "PaymentsInTheEventOfCommercializationOfTechnology", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PaymentsUponCompletionOfIrbClinicalTrial": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments Upon Completion Of The Irb Clinical Trial" } } }, "localname": "PaymentsUponCompletionOfIrbClinicalTrial", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PaymentsUponDosingOfFirstPatientInPhase12ClinicalTrial": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments Upon Dosing Of The First Patient In A Phase 1-2 Clinical Trial" } } }, "localname": "PaymentsUponDosingOfFirstPatientInPhase12ClinicalTrial", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PaymentsUponDosingOfFirstPatientInPhase3ClinicalTrial": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments Upon Dosing Of The First Patient In Phase 3 Clinical Trial" } } }, "localname": "PaymentsUponDosingOfFirstPatientInPhase3ClinicalTrial", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PaymentsUponFilingIndWithFda": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments Upon Filing An Ind With The Fda" } } }, "localname": "PaymentsUponFilingIndWithFda", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PaymentsUponSigningAgreementWithUniversityForInitiationOfIrbClinicalTrial": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments Upon Signing Agreement With University For The Initiation Of An Irb Clinical Trial" } } }, "localname": "PaymentsUponSigningAgreementWithUniversityForInitiationOfIrbClinicalTrial", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PercentageOfDiscountOnTheBasisOfRecentTradingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage Of Discount On The Basis Of Recent Trading Price" } } }, "localname": "PercentageOfDiscountOnTheBasisOfRecentTradingPrice", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_PlacementAgentFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Placement agent fee to ROATH" } } }, "localname": "PlacementAgentFee", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PreFundedWarrantsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants Exercise price" } } }, "localname": "PreFundedWarrantsExercisePrice", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "celz_PreferredStockRedemptionsAmounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Preferred stock redemption, amount" } } }, "localname": "PreferredStockRedemptionsAmounts", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_ProceedsFromDirector": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds From Director" } } }, "localname": "ProceedsFromDirector", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_ProceedsFromSalesOfPreferredStockAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Proceeds from sales of preferred stock, amount" } } }, "localname": "ProceedsFromSalesOfPreferredStockAmount", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_ProceedsFromSalesOfPreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds from sales of preferred stock, shares" } } }, "localname": "ProceedsFromSalesOfPreferredStockShares", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "celz_PurchaseOfPreFundedWarrantAndRelatedCommonWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase of Pre-Funded Warrant and related Common Warrant" } } }, "localname": "PurchaseOfPreFundedWarrantAndRelatedCommonWarrant", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_PurchaseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase of warrants shares" } } }, "localname": "PurchaseOfWarrantsShares", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_ReimbursementOfManagementFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reimbursement of management fees monthly" } } }, "localname": "ReimbursementOfManagementFees", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_RemainingPortionOfObligationPaidInCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Remaining portion of obligation paid in cash" } } }, "localname": "RemainingPortionOfObligationPaidInCash", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_RestrictedCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Restricted Common Stock" } } }, "localname": "RestrictedCommonStock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_RisksAndUncertaintiespolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks And Uncertainties" } } }, "localname": "RisksAndUncertaintiespolicyTextBlock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "celz_RothCapitalPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Roth Capital Partners [Member]" } } }, "localname": "RothCapitalPartnersMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_RoyaltyPaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalty Payment Percentage" } } }, "localname": "RoyaltyPaymentPercentage", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "celz_ScenarioOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scenario One [Member]" } } }, "localname": "ScenarioOneMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_ScenarioTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scenario Two [Member]" } } }, "localname": "ScenarioTwoMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_ScheduleOfIssuancesAndExercisesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of issuances and exercises" } } }, "localname": "ScheduleOfIssuancesAndExercisesTableTextBlock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "celz_ScheduleOfLicensingAgreementsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month", "label": "Schedule Of Licensing Agreements" } } }, "localname": "ScheduleOfLicensingAgreementsTableTextBlock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsTables" ], "xbrltype": "textBlockItemType" }, "celz_ScheduleValueOfOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Warrants" } } }, "localname": "ScheduleValueOfOptionsTableTextBlock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "celz_SeriesAPreferredStockDescriptionOfSurrenderAndExchange": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Surrender And Exchange Description" } } }, "localname": "SeriesAPreferredStockDescriptionOfSurrenderAndExchange", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_SeriesAPreferredStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock Issued" } } }, "localname": "SeriesAPreferredStockSharesIssued", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_SeriesAPreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A, Preferred Stock" } } }, "localname": "SeriesAPreferredStocksMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "celz_SeriesBPreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B, Preferred Stock" } } }, "localname": "SeriesBPreferredStocksMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "celz_SeriesCPreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series C, Preferred Stock" } } }, "localname": "SeriesCPreferredStocksMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "celz_SharePriceForTwoOrMoreConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Price For Two Or More Consecutive Trading Days" } } }, "localname": "SharePriceForTwoOrMoreConsecutiveTradingDays", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_StemSpinePatentPurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StemSpine Patent Purchase [Member]" } } }, "localname": "StemSpinePatentPurchaseMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_StemspineLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stemspine LLC [Member]" } } }, "localname": "StemspineLLCMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_StockBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Stock-based compensation]", "verboseLabel": "Stock-based compensation" } } }, "localname": "StockBasedCompensation", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_StockIssuedDuringPeriodValueStockOptionsExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise price" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercise", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "celz_StockIssuedToCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock issued to common stock" } } }, "localname": "StockIssuedToCommonStock", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_StockPriceGrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock price granted" } } }, "localname": "StockPriceGrants", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "celz_StockholdersEquityabstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS EQUITY (Details Narrative)" } } }, "localname": "StockholdersEquityabstract", "nsuri": "http://celz.com/20220930", "xbrltype": "stringItemType" }, "celz_ValueOfOptionsVest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Options vested, value" } } }, "localname": "ValueOfOptionsVest", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_WarrantsIssuedWithNotesPayableAsAServiceFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Warrants issued with notes payable as a service fee" } } }, "localname": "WarrantsIssuedWithNotesPayableAsAServiceFee", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "celz_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://celz.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "celz_WeightedAverageCommonSharesOutstandingUsedInCalculatingBasicEarningsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Common Shares Outstanding Used In Calculating Basic Earnings Per Share" } } }, "localname": "WeightedAverageCommonSharesOutstandingUsedInCalculatingBasicEarningsPerShare", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "celz_WeightedAverageExercisePriceOutstandingEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted Average Exercise Price, Outstanding ending]", "verboseLabel": "Weighted Average Exercise Price, Outstanding ending" } } }, "localname": "WeightedAverageExercisePriceOutstandingEnding", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "celz_WeightedAverageLifeRemainingOutstandingBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Life Remaining, Outstanding beginning" } } }, "localname": "WeightedAverageLifeRemainingOutstandingBeginning", "nsuri": "http://celz.com/20220930", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "durationItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "label": "CEO [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r69", "r170", "r175", "r181", "r289", "r290", "r294", "r295", "r331", "r413" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r69", "r170", "r175", "r181", "r289", "r290", "r294", "r295", "r331", "r413" ], "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r186", "r217", "r246", "r248", "r344", "r345", "r346", "r347", "r348", "r349", "r368", "r404", "r405", "r414", "r415" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "verboseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative", "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r186", "r217", "r246", "r248", "r344", "r345", "r346", "r347", "r348", "r349", "r368", "r404", "r405", "r414", "r415" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "verboseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative", "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r164", "r166", "r167", "r168", "r169", "r186", "r217", "r244", "r246", "r248", "r274", "r275", "r276", "r344", "r345", "r346", "r347", "r348", "r349", "r368", "r404", "r405", "r414", "r415" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative", "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r164", "r166", "r167", "r168", "r169", "r186", "r217", "r244", "r246", "r248", "r274", "r275", "r276", "r344", "r345", "r346", "r347", "r348", "r349", "r368", "r404", "r405", "r414", "r415" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative", "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r79", "r84", "r165", "r247" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r79", "r84", "r165", "r247", "r336" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r18", "r334" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r135", "r136" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r11", "r334" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r71", "r72", "r73", "r278", "r279", "r280", "r303" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r40", "r54", "r203", "r318" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discounts" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r54", "r156", "r161" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of patent costs", "terseLabel": "Amortization Expenses", "verboseLabel": "Amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti-dilutive Securities Excluded From Computation Of Earning Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://celz.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://celz.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r8", "r66", "r121", "r124", "r129", "r143", "r170", "r171", "r172", "r174", "r175", "r176", "r177", "r178", "r179", "r181", "r182", "r289", "r294", "r309", "r332", "r334", "r387", "r396" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r17", "r66", "r143", "r170", "r171", "r172", "r174", "r175", "r176", "r177", "r178", "r179", "r181", "r182", "r289", "r294", "r309", "r332", "r334" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r70", "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r6", "r334", "r411", "r412" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r50", "r56", "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "ENDING CASH BALANCE", "periodStartLabel": "BEGINNING CASH BALANCE" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r50", "r310" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "totalLabel": "NET INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositAtCarryingValue": { "auth_ref": [ "r6" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Sale of shares of common stock" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r71", "r72", "r303" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, Shares Par Value" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common shares auhorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares Issued", "verboseLabel": "Common Stock Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r230" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r10", "r334" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value, 25,000,000,000 and 6,000,000,000 shares authorized; 14,076,246 and 6,338,872 issued and 14,076,238 and 6,338,864 outstanding at September 30, 2022 and December 31, 2021, respectively", "verboseLabel": "Common stock value" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets", "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r62", "r291" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Organization" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r183", "r184", "r185", "r186", "r194", "r195", "r196", "r199", "r200", "r201", "r202", "r203", "r209", "r210", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r37", "r66", "r143", "r170", "r171", "r172", "r175", "r176", "r177", "r178", "r179", "r181", "r182", "r309" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentRate": { "auth_ref": [ "r58", "r60" ], "lang": { "en-us": { "role": { "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.", "label": "Conversion Price, Percentage" } } }, "localname": "DebtConversionConvertedInstrumentRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DEBT" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r64", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r197", "r204", "r205", "r207", "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Day" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r22", "r200", "r319" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Risk free interest" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r22", "r208", "r319", "r321" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Interest Rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r194", "r318", "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Unamortized Debt Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r54", "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "[Depreciation, Depletion and Amortization, Nonproduction]", "verboseLabel": "Amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainOnDerivative": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.", "label": "Relief of derivative liabilities" } } }, "localname": "DerivativeGainOnDerivative", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DERIVATIVE LIABILITIES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r301", "r306" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Liabilities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKBASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r18", "r68", "r173", "r175", "r176", "r180", "r181", "r182", "r327" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Advances from related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r35", "r76", "r77", "r78", "r79", "r80", "r86", "r89", "r101", "r102", "r103", "r106", "r107", "r304", "r305", "r391", "r400" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "BASIC NET INCOME (LOSS) PER SHARE" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r35", "r76", "r77", "r78", "r79", "r80", "r89", "r101", "r102", "r103", "r106", "r107", "r304", "r305", "r391", "r400" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "DILUTED NET INCOME (LOSS) PER SHARE" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r104", "r105" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Basic and Diluted Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r28", "r29", "r30", "r71", "r72", "r73", "r75", "r81", "r83", "r108", "r144", "r230", "r232", "r278", "r279", "r280", "r283", "r284", "r303", "r311", "r312", "r313", "r314", "r315", "r316", "r323", "r406", "r407", "r408" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r138", "r139", "r140", "r141", "r142", "r145", "r146", "r147", "r148", "r149", "r152", "r153", "r154", "r155", "r206", "r228", "r301", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r422", "r423", "r424", "r425", "r426", "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableRevolving": { "auth_ref": [ "r150", "r151" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of financing receivable that can be withdrawn, repaid, and redrawn.", "label": "Financing Fees" } } }, "localname": "FinancingReceivableRevolving", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r157", "r158", "r160", "r162", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r157", "r159" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r160", "r371" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Licenses, net of amortization" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r54", "r213", "r214" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "[Gain (Loss) on Extinguishment of Debt]", "negatedLabel": "Gain on extinguishment of convertible notes" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r36", "r66", "r121", "r123", "r125", "r128", "r130", "r143", "r170", "r171", "r172", "r175", "r176", "r177", "r178", "r179", "r181", "r182", "r309" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r33", "r121", "r123", "r125", "r128", "r130", "r385", "r389", "r393", "r401" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 16.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]", "totalLabel": "INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r67", "r82", "r83", "r120", "r282", "r285", "r286", "r402" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 15.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash payments for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r53" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "[Increase (Decrease) in Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r53" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "[Increase (Decrease) in Accounts Receivable]", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r53" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "[Increase (Decrease) in Accrued Liabilities]", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r53" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Inventories]", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r90", "r91", "r92", "r103" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Effect Of Warrants" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r97", "r98", "r103" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Effect Of Convertible Notes Payable" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r31", "r119", "r317", "r320", "r392" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 12.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "auth_ref": [ "r88", "r94", "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.", "label": "Add - Interest On Convertible Notes Payable" } } }, "localname": "InterestOnConvertibleDebtNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r48", "r51", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash payments for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r16", "r334" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r15", "r66", "r143", "r309", "r334", "r388", "r398" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r21", "r66", "r143", "r170", "r171", "r172", "r175", "r176", "r177", "r178", "r179", "r181", "r182", "r290", "r294", "r295", "r309", "r332", "r333", "r334" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueAdjustment": { "auth_ref": [], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.", "label": "[Liabilities, Fair Value Adjustment]", "negatedLabel": "Change in fair value of derivatives liabilities" } } }, "localname": "LiabilitiesFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManagementFeePayable": { "auth_ref": [], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust.", "label": "Management fee and patent liabilities - related parties" } } }, "localname": "ManagementFeePayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r50" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 27.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r50" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 28.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r50", "r52", "r55" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 29.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r26", "r27", "r30", "r34", "r55", "r66", "r74", "r76", "r77", "r78", "r79", "r82", "r83", "r99", "r121", "r123", "r125", "r128", "r130", "r143", "r170", "r171", "r172", "r175", "r176", "r177", "r178", "r179", "r181", "r182", "r305", "r309", "r390", "r399" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "totalLabel": "NET INCOME (LOSS)", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r76", "r77", "r78", "r79", "r86", "r87", "r100", "r103", "r121", "r123", "r125", "r128", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income As Reported" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r88", "r93", "r94", "r95", "r96", "r100", "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income Available To Common Stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 13.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "[Nonoperating Income (Expense)]", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME/(EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r58", "r59", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Convertible notes issued" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "TOTAL EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r121", "r123", "r125", "r128", "r130" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 14.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Option [Member]" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r70", "r85", "r116", "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization And Summary Of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r7", "r386", "r395" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER ASSETS" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r403" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Carrying Value Of Patent" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r47" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "[Payments of Debt Issuance Costs]", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit": { "auth_ref": [ "r43" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use.", "label": "[Payments to Acquire Restricted Certificates of Deposit]", "negatedLabel": "Purchase of certificates of deposit" } } }, "localname": "PaymentsToAcquireRestrictedCertificatesOfDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": { "auth_ref": [ "r42", "r326" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.", "label": "[Payments to Fund Long-Term Loans to Related Parties]", "negatedLabel": "Advance to related party" } } }, "localname": "PaymentsToFundLongtermLoansToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r249", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendsShares": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.", "label": "Preferred stock redemption, shares" } } }, "localname": "PreferredStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ProceedsFromCollectionOfAdvanceToAffiliate": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the collection of money previously advanced to an entity that is related to it but not strictly controlled.", "label": "Advanced received" } } }, "localname": "ProceedsFromCollectionOfAdvanceToAffiliate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r45" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from convertible notes payable", "verboseLabel": "Proceeds from convertible notes payable" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r44" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock and warrants, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r44" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from sale of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Warrants issued with notes payable" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r45" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from note payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r45" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Related party advances" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r44" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r26", "r27", "r30", "r49", "r66", "r74", "r82", "r83", "r121", "r123", "r125", "r128", "r130", "r143", "r170", "r171", "r172", "r175", "r176", "r177", "r178", "r179", "r181", "r182", "r288", "r292", "r293", "r296", "r297", "r305", "r309", "r393" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "negatedLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r245", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r245", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r245", "r326", "r328", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r324", "r325", "r327", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r46" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "[Repayments of Convertible Debt]", "negatedLabel": "Payments to settle convertible notes payable and warrants" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r46" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "[Repayments of Notes Payable]", "negatedLabel": "Payments on notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r46" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "[Repayments of Related Party Debt]", "negatedLabel": "Repayment of related party advances" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r281", "r369", "r416" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r12", "r232", "r334", "r397", "r409", "r410" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r71", "r72", "r73", "r75", "r81", "r83", "r144", "r278", "r279", "r280", "r283", "r284", "r303", "r406", "r408" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r63", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r32", "r66", "r117", "r118", "r122", "r126", "r127", "r131", "r132", "r133", "r143", "r170", "r171", "r172", "r175", "r176", "r177", "r178", "r179", "r181", "r182", "r309", "r393" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Basic And Diluted Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r252", "r267", "r270" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r38" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r53" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Life Remaining, Outstanding ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate]", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Issued", "terseLabel": "Issuances", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1", "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Outstanding at the end", "periodStartLabel": "Outstanding at the begining" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1", "http://celz.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted Average Exercise Price, Outstanding ending", "periodStartLabel": "Weighted Average Exercise Price, Outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "[Share Price]", "verboseLabel": "Common stock price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails", "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Fair Value Assumptions, Expected Term", "verboseLabel": "Expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted Average Life Remaining, Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Weighted Average Exercise Price, Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r25", "r28", "r29", "r30", "r71", "r72", "r73", "r75", "r81", "r83", "r108", "r144", "r230", "r232", "r278", "r279", "r280", "r283", "r284", "r303", "r311", "r312", "r313", "r314", "r315", "r316", "r323", "r406", "r407", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative", "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative", "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails1", "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetails", "http://celz.com/role/StockholdersEquityDetailsNarrative", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r71", "r72", "r73", "r108", "r370" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/DebtDetailsNarrative", "http://celz.com/role/DerivativeLiabilitiesDetailsNarrative", "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails1", "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetails", "http://celz.com/role/StockholdersEquityDetailsNarrative", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r24", "r198", "r230", "r231", "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r9", "r10", "r230", "r232", "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercised", "verboseLabel": "Exercises" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1", "http://celz.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r25", "r230", "r232" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r10", "r13", "r14", "r66", "r137", "r143", "r309", "r334" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKBASED COMPENSATION (Details)" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r65", "r216", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r232", "r234", "r302" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r335", "r337" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit": { "auth_ref": [ "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit.", "label": "Fdic Insured Amount" } } }, "localname": "TimeDepositsAtOrAboveFDICInsuranceLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r138", "r139", "r140", "r141", "r142", "r206", "r228", "r301", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r422", "r423", "r424", "r425", "r426", "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r109", "r110", "r111", "r112", "r113", "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r88", "r103" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - DILUTED", "verboseLabel": "Weighted Average Common Shares Outstanding Used In Calculating Diluted Earnings Per Share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r86", "r103" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919232-210447" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r306": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r417": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r418": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r419": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r420": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r421": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r422": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r423": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r424": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r425": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r426": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r427": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r428": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r429": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" } }, "version": "2.1" } ZIP 51 0001477932-22-008323-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-22-008323-xbrl.zip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
6Z]4:M)IP*S%YH7UX+%?X7UQ@!>=>B6_/V/=MB+W!?13XBYR9M:5MV@
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end

Date: November 10, 2022	By:	/s/ Timothy Warbington
		Timothy Warbington
		Chief Executive Officer
		(Principal Executive Officer)

Date: November 10, 2022	By:	/s/ Donald Dickerson
		Donald Dickerson
		Chief Financial Officer
		(Principal Financial Officer)